

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 February 2007 (01.02.2007)

PCT

(10) International Publication Number
WO 2007/012138 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/AU2006/001065

(22) International Filing Date: 28 July 2006 (28.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2005904085 29 July 2005 (29.07.2005) AU

(71) Applicant (for all designated States except US): **HYBRID BIOSCIENCES PTY LTD** [AU/AU]; Evandale House, 80 Evandale Street, Floreat, Western Australia 6014 (AU).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KAY, Peter Hamilton** [AU/AU]; 80 Evandale Street, Floreat, Western Australia 6014 (AU).

(74) Agent: **GRIFFITH HACK**; Level 19, 109 St George's Terrace, Perth, Western Australia 6000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2007/012138 A1

(54) Title: IDENTIFICATION OF GENES AND THEIR PRODUCTS WHICH PROMOTE HYBRID VIGOUR OR HYBRID DEBILITY AND USES THEREOF

(57) Abstract: The present invention relates to a method of identifying candidate genes and the proteins enclosed by them that are useful in the inducement of hybrid vigour, hybrid debility and/or the diagnosis, prognosis and treatment of disease. In particular, the present invention relates to a method for identifying candidate genes capable of producing hybrid vigour or hybrid debility in an animal or plant, comprising the steps of: (i) comparing the mRNA sequence of alleles of candidate genes isolated from an animal or plant which exhibits hybrid vigour or hybrid debility with the nucleotide sequences from the corresponding alleles isolated from the parents of said animal or plant; (ii) identifying mRNA sequence differences in the alleles from said animal or plant which exhibits hybrid vigour or hybrid debility which codes for amino acid sequence variation; and (iii) identifying that the amino acid sequence variation between alleles of the candidate gene in said animal or plant is encoded by mRNA sequences which are located within two or more different exons within the candidate gene.

IDENTIFICATION OF GENES AND THEIR PRODUCTS WHICH PROMOTE
HYBRID VIGOUR OR HYBRID DEBILITY AND USES THEREOF

5 FIELD

The invention relates to a method of identifying candidate genes and the proteins encoded by them that are useful in the inducement of hybrid vigour, hybrid debility and/or
10 diagnosis, prognosis and treatment of disease. In particular, the present invention relates to a method of identifying factors leading to hybrid vigour or hybrid debility comprising identifying the presence or absence of multiple species of mRNA or protein encoded by alleles of
15 a candidate gene, wherein the presence of multiple species of mRNA or protein is indicative of hybrid vigour or hybrid debility.

BACKGROUND

20

It has been recognised for hundreds of years that some genetic factors that have the capacity to influence growth, viability, pest-resistance or robustness of crops, vegetables, fruit and animals such as cattle, sheep and
25 pigs for example are more influential in offspring of genetically unrelated biologically normal parents. This biological phenomenon is referred to as hybrid vigour (HV) or heterosis. Offspring of genetically unrelated parents are referred to as heterozygous organisms.

30

A further well known form of HV, in which an almost normal biological phenotype is restored in offspring of biologically defective parents, each of which carry different mutational forms of the same gene is referred to
35 as intragenic or interallelic complementation (IC).

It is difficult to over-estimate the commercial

significance and future utility of HV. In the field of agriculture alone, for example, application of HV yields multi-billion dollar returns and reflects one of the greatest applied achievements in the field of genetics
5 (see, for example, Alam et al. (2004), *J. Zhejiang Uni. Sci.* 5, 406).

The International Food Policy Research Institute has predicted a 100% increase in the demand for meat in the
10 developing world by the year 2020, compared to 1995 consumption levels (Pinstrup-Anderson et al., in: 2020 Vision Food Policy Report, International Food Policy Institute, Washington DC). With respect to food crops, in India alone, it is predicted that food output will need to
15 be doubled by the year 2025 and even trebled by 2050 to support the predicted population growth (Sengupta et al., (2001), *Curr. Genomics*, 2, 181). In spite of the estimated future global food requirements, the rate of increase of food crop production has decreased in recent years,
20 particularly in the 1990s, to approximately 1% per annum (Conway & Toennissen, (1999), *Nature*, 402, C55). Therefore development and application of new technologies that promote HV are essential to ensure that the demands for increases in the future global production rate of food
25 crops and animals are met.

The view has long been held that HV is driven by novel proteins (such as hormones, enzymes or growth factors) synthesised uniquely in heterozygous or hybrid organisms
30 (see, for example, Gill, (1977), In: *Genetics and Wheat Improvement*, A.K. Gupta, Ed. (Oxford and IBH Publishing Co. New Delhi, pp 204-207; Scandalios et al., (1972), *Arch. Biochem. Biophys.* 153, p695; Romagnoli et al., (1990), *Theor. Appl. Genet.* 80, p769; Cheng et al.,
35 (1996), *Chinese Sci.Bull.* 41, p40).

Because it had always been difficult to understand how

novel proteins could be formed in heterozygous offspring, many alternative models have been proposed to explain HV. In recent times a model akin to electric circuitry (Milborrow (1998), *J. Exp. Bot.* 49, p1063) and another
5 mathematically based model (Gordon (1999), *Heredity*, 83, p757) have been put forward. However, as stated by Birchler et al., (2003), *The Plant Cell*, 15, p2236 and more recently by Syed & Chen, (2005), *Heredity*, 94, p295, the underlying molecular genetic mechanism driving HV or
10 heterosis remains unknown. In 2003, Birchler and colleagues also predicted that "an eventual molecular explanation of heterosis will determine whether it can be manipulated for the benefit of agriculture and
biotechnology."

15

As early as 1960, it was shown that hybrid proteins can be formed in heterozygous offspring (Schwartz, (1960), *Proc. Natl. Acad. Sci. USA*, 46, p1210). The same worker also postulated that HV was driven by these hybrid proteins.
20 Over a decade later, this postulate was proven to be correct when it was confirmed that HV is associated with the formation of novel or hybrid proteins (Wills & Nichols (1972), *Proc. Natl. Acad. Sci. USA*, 69, p323; Singh et al., (1975), *Genetics*, 80, p637).

25

In more recent times, unique mRNA species that generate novel proteins and which are absent in either parent have been clearly identified in heterozygous chickens that display different forms of hybrid vigour (Sun et al.,
30 (2005) *Animal Genetics*, 36, p210).

Some hybrid proteins formed in heterozygous offspring may, in contrast to HV, reduce the robustness, viability or well-being of, or cause disease in an offspring compared
35 to either of its parents. This phenomenon is referred to as hybrid debility (HD^o) (see our co-pending International Patent Application No. PCT/AU2005/000141). Some forms of

HD may be caused directly by inappropriate or abnormal activity of a hybrid protein in a heterozygous offspring compared to the activity of the wild-type parental protein. Examples of human diseases in this category
5 include type 2 diabetes as well as thromboembolic disease in patients suffering from systemic lupus erythematosus. With respect to type 2 diabetes, results of many studies have shown that an enzyme referred to as a novel calpain-like cysteine protease encoded by the gene (*CAPN10*) is
10 involved in the disease process. Cox (2001), has evaluated the collective results of these studies with respect to genetic variability of *CAPN10* and concluded that, "individuals heterozygous for the two different (*CAPN10*)
15 haplotypes that form the high-risk combination have ~3-fold increased risk relative to all other combinations of haplotypes, and ~7-fold increased risk relative to the lowest risk haplotype combination. Individuals homozygous for either of the haplotypes in the high-risk combination were not at increased risk of developing type 2 diabetes"
20 (*Hum. Mol. Genet.* 10, p2301).

On the other hand, some forms of HD may be caused indirectly as a consequence of a hybrid protein being recognized as immunologically foreign by the host's immune
25 system. Examples of diseases in this category include type 1 diabetes and auto-immune liver disease. Some patients suffering from type 1 diabetes have auto-antibodies in their blood which are directed against a constituent of the islet cells, the cells in the pancreas
30 that produce insulin. The target of these auto-antibodies is glutamic acid decarboxylase (*GAD65*).

In keeping with the immunological induction mode of HD, investigations by Boutin *et al.*, (2003) (*PLoS Biol.* 1,
35 p68) have confirmed that immunity to the type 1 diabetes target auto-antigen *GAD65* is increased in subjects who are heterozygous for different genetic forms of *GAD65*.

In spite of the major commercial significance of the application of HV in agriculture, horticulture and aquaculture and the extensive international research efforts aimed at understanding the underlying molecular genetic basis of HV and HD, thus far no genes have been identified that drive either of these two phenotypes in plants or animals or fish. The main reason for this is because the currently available methods of identifying or mapping of genes that cause advantageous or disadvantageous phenotypes, including diseases, rely upon the use of a series of genetic markers distributed throughout the genome of the organism under examination. Usually these genetic markers comprise a set of single nucleotide polymorphisms or SNPs. Relevant genes are then located by determining which SNPs segregate most closely or are co-inherited with the biological trait or disease under investigation. Co-segregation studies are most effective when SNP analyses are applied to as many generations as possible of a pedigree in which some members of the family have the disease or phenotype under investigation. This method of identification of relevant genes is highly successful when the disease or phenotype is passed on through each generation in accordance with a Mendelian mode of inheritance. However, as heritability of HV and HD does not conform to a Mendelian mode of inheritance these techniques are unable to identify the genes involved in HD or HV.

There is therefore, a need for a method of identifying genes involved in promotion of HV and HD. Moreover, there is a need for a method of determining which hybrid proteins are responsible for the induction of HV or HD.

35 SUMMARY

In order to synthesise novel polypeptides or proteins,

inventor has postulated that during the process of splicing, hybrid mRNA molecules could be generated in vivo by a primary RNA splicing mechanism that allows ligation of the 3' end of an exon from a gene inherited from one parent with the 5' end of the next downstream exon from the same gene inherited from the other parent. It is important to realize that the mechanism for generating hybrid gene products herein is different from others recognized thus far (see, for example, Mongelard et al., (2002), *Genetics*, 160, p1481) in which compound proteins may be formed by fusion of primary RNA species originating from different strands of DNA on the same chromosome or different transcriptional units from the same parental source. Thus Mongelard et al describe the ligation of two separate transcriptional units of different strands of DNA. In contrast, the inventor has shown that novel or hybrid mRNA molecules, from which novel hybrid proteins can be synthesized, are generated by a biochemical pathway that incorporates exons or parts thereof from each of the two different parental allelic transcriptional units into the same mature mRNA molecule.

Consequently, in the broadest aspect of the present invention, there is described a molecular genetic mechanism that explains how the biological phenotypes of HV and HD are generated in heterozygous offspring. The novel genetic structures formed in heterozygous offspring and which generate HV and HD are not obvious by reference to the heritable genetic code of their parents.

30

Accordingly, in a first aspect, the present invention provides a method for identifying candidate genes capable of producing hybrid vigour or hybrid debility in an animal or plant, comprising the steps of:

35 (i) comparing the mRNA sequence of alleles of candidate genes isolated from an animal or plant which exhibits hybrid vigour or hybrid debility with the

nucleotide sequences from the corresponding alleles isolated from the parents of said animal or plant;

(ii) identifying mRNA sequence differences in the alleles from said animal or plant which exhibits hybrid vigour or hybrid debility which codes for amino acid sequence variation; and

(iii) identifying that the amino acid sequence variation between alleles of the candidate gene in said animal or plant is encoded by mRNA sequences which are located within two or more different exons within the candidate gene.

In a second aspect the present invention provides a method of identifying factors leading to hybrid vigour or hybrid debility comprising the steps of:

(i) identifying the presence or absence of multiple species of mRNA or protein encoded by alleles of a candidate gene; and

(ii) if multiple species of mRNA or protein are present then analysing said species of mRNA or protein to determine if said species have nucleotide or amino acid sequence variations, respectively corresponding to variations in two or more exons;

wherein the presence of multiple species of mRNA or protein at step (ii) is indicative of hybrid vigour or hybrid debility.

A third aspect provides a method for producing hybrid vigour or hybrid debility in an animal or plant, comprising the steps of:

(i) identifying the presence or absence of multiple species of mRNA or protein encoded by alleles of a candidate gene; and

(ii) if multiple species of mRNA or protein are present then analysing said species of mRNA or protein to determine if said species have nucleotide or amino acid sequence variations, respectively corresponding to

variations in two or more exons; wherein the presence of multiple species of mRNA or protein at step (ii) is indicative of hybrid vigour or hybrid debility;

(iii) determining the function of the multiple species of proteins compared to the function of a wild-type protein control to determine which species promotes HV or HD in said plant or animal;

(iv) preparing a construct comprising nucleotide sequence encoding said protein species in step (iii);

(v) transforming said construct into a recipient plant or animal cell; and

(vi) regenerating a plant or animal, which expresses said construct, from said cell.

In a fourth aspect the invention provides a method of detecting the presence or absence of hybrid mRNA in a plant or animal comprising the step of isolating mRNA from a plant or animal and comparing the nucleotide sequence of said mRNA to the corresponding coding sequence of the plant or animal's alleles.

A fifth aspect provides a construct comprising a synthetic gene comprising exons from different alleles of a gene, wherein said alleles code for amino acid sequence variation wherein the variation occurs between different alleles.

The present invention further relates to the use of hybrid mRNA molecules produced in vivo or the hybrid proteins translated by them to overcome disease in a plant or animal and/or induce hybrid vigour in a plant or animal.

The plant cell may be isolated from any higher plant, including gymnosperms, monocotyledonous and dicotyledonous plants, although all agriculturally important plant species are preferred. Preferably, the plant cell is isolated from a plant selected from the group consisting

of barley, rye, sorghum, maize, soybean, wheat, corn, potato, cotton, rice, oilseed rape (including canola), sunflower, alfalfa, sugarcane, banana, blackberry, blueberry, strawberry, and raspberry, cantaloupe, carrot, cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous fruits (such as apple, peach, pear, cherry and plum) and vegetable brassicas (such as broccoli, cabbage, cauliflower, brussel sprouts and kohlrabi). Other crops, fruits and vegetables whose phenotype may be changed include barley, currant, avocado, citrus fruits such as oranges, lemons, grapefruit and tangerines, artichoke, cherries, nuts such as the walnut and peanut, endive, leek, roots, such as arrowroot, beet, cassava, turnip, radish, yam, sweet potato and beans. Other plant cells that might used in the present invention include cells isolated from woody species, such pine, poplar and eucalyptus. More preferably, the plant cell is a rice cell, a wheat cell, a barley cell, a rye cell, a sorghum cell or a maize cell.

The step of transforming the plant cell comprises any method known in the art, which is capable of stably transforming the plant cell. Suitable protocols are available for Leguminosae (alfalfa, soybean, clover, etc.), Umbelliferae (carrot, celery, parsnip), Cruciferae (cabbage, radish, rapeseed, broccoli, etc.), Curcubitaceae (melons and cucumber), Gramineae (wheat, corn, rice, barley, millet, etc.), Solanaceae (potato, tomato, tobacco, peppers, etc.), and various other crops. See protocols described in Ammirato et al. (1984) Handbook of Plant Cell Culture--Crop Species. Macmillan Publ. Co. Shimamoto et al. (1989) Nature 338:274-276; Fromm et al. (1990) Bio/Technology 8:833-839; and Vasil et al. (1990) Bio/Technology 8:429-434.

Preferably, the plant cell is transformed by a method selected from the group consisting of homologous recombination for example using technologies based on the use of meganuclease 1-SceI, or microprojectile
5 bombardment, PEG mediated transformation of protoplasts, electroporation, silicon carbide fibre mediated transformation, or Agrobacterium-mediated transformation. In a preferred embodiment of the invention the step of transforming comprises microprojectile bombardment by
10 coating microprojectiles with DNA comprising the construct and contacting the recipient cells with the microprojectiles.

In a sixth aspect, the invention provides use of hybrid
15 protein molecules produced in vitro or in vivo to overcome hybrid debility in a plant or animal and/or induce hybrid vigour in a plant or animal comprising the step of introducing said hybrid protein into said animal or plant.

20 The animal cells can be isolated from any animal although it is particularly useful for mammals and fish. Suitable mammalian sources include members of the Orders Primates, Rodentia, Lagomorpha, Cetacea, Carnivora, Perissodactyla and Artiodactyla. Members of the Orders Perissodactyla
25 and Artiodactyla are particularly preferred because of their similar biology and economic importance.

For example, Artiodactyla comprise approximately 150 living species distributed through nine families: pigs
30 (Suidae), peccaries (Tayassuidae), hippopotamuses (Hippopotamidae), camels (Camelidae), chevrotains (Tragulidae), giraffes and okapi (Giraffidae), deer (Cervidae), pronghorn (Antilocapridae), and cattle, sheep, goats and antelope (Bovidae). Many of these animals are
35 used as feed animals in various countries. More importantly, with respect to the present invention, many of the economically important animals such as goats,

sheep, cattle and pigs have very similar biology and share high degrees of genomic homology.

The Order Perissodactyla comprises horses and donkeys, which are both economically important and closely related. Indeed, it is well known that horses and donkeys interbreed.

In one embodiment, the animal cells will be obtained from an ungulate. Preferably, the ungulate is selected from the group consisting of domestic or wild representatives of bovids, ovids, cervids, suids, equids and camelids. Examples of such representatives are cows or bulls, bison, buffalo, sheep, big-horn sheep, horses, ponies, donkeys, mule, deer, elk, caribou, goat, water buffalo, camels, llama, alpaca, and pigs. Especially preferred in the bovine species are *Bos taurus*, *Bos indicus*, and *Bos* buffaloes cows or bulls.

In one embodiment the animal cells are isolated from aquatic organisms such as vertebrate and invertebrate marine animals. More preferably the aquatic organism is selected from the group consisting of fish, amphibians and molluscs. Fish include; but are not limited to, zebrafish, European carp, salmon, mosquito fish, tench, lampreys, round gobies, tilapia and trout. Amphibians include; but are not limited to, toads and frogs. Molluscs include; but are not limited to, Pacific oysters, zebra mussels, striped mussels, New Zealand screw shells, the Golden Apple Snail, the Giant African Snail, and the disease vectoring snails in the genera *Biomphalaria* and *Bulinus*.

Transformation of constructs of the invention into animal cells is preferably by homologous recombination. Homologous recombination (see Molecular Genetics, U. Melcher (1998)) is preferably induced by addition of the

engineered construct to cells such as embryonic stem cells grown in tissue culture which contain the targeted gene. More preferably, transformed stem cells are injected into a new blastocyst causing fixation of the new construct in the mature animal.

DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

All publications mentioned herein are cited for the purpose of describing and disclosing the protocols and reagents which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

The practice of the present invention employs, unless otherwise indicated, conventional molecular biology, plant and animal biology, and recombinant DNA techniques within the skill of the art. Such techniques are well known to the skilled worker, and are explained fully in the literature. See, eg., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual" (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover, Ed., 1985); "Oligonucleotide Synthesis" (M.J. Gait, Ed., 1984); "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins, eds., 1985); "Transcription and Translation" (B.D. Hames & S.J. Higgins, eds., 1984); B. Perbal, "A Practical Guide to Molecular Cloning" (1984), and Sambrook, et al., "Molecular Cloning: a Laboratory Manual" 12th edition (1989).

It is understood that the invention is not limited to the particular materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and it is not intended to limit the

scope of the present invention which will be limited only by the appended claims. It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the
5 context clearly dictates otherwise. Thus, for example, a reference to "a plant cell" includes a plurality of such plant cells, and a reference to "an animal cell" is a reference to one or more animal cells. Although any materials and methods similar or equivalent to those
10 described herein can be used to practice or test the present invention, the preferred materials and methods are now described.

In one of the broadest aspects of the present invention
15 there is described a novel mechanism by which hybrid mRNA and/or hybrid protein are formed. More importantly, as described herein, the present invention describes a mechanism which explains the phenomenon of hybrid vigour (HV) and hybrid debility (HD[®]).


20 HV occurs when an offspring displays an enhanced form of any particular biological phenotype when compared to expression of the same biological phenotype in either of its parents. HD[®] occurs when an offspring displays a
25 reduced form of any particular biological phenotype or disease when compared to its parents.

The biological phenotype of HD may be caused directly by a
30 reduction in the activity of hybrid proteins such as enzymes. On the other hand, some hybrid proteins may be recognised as immunologically foreign and cause the onset of some forms of HD by inducing an auto-immune process.

The terms "hybrid mRNA" and "hybrid protein" as used
35 herein refers to the different or multiple species of mRNA and/or protein that are produced during transcription and/or translation of the alleles of a single gene.

An example of the range of hybrid proteins that have the potential to be formed by the mechanism of trans-exonic assembly of hybrid mRNA molecules described herein is shown in the Figure 1. The hybrid proteins encoded by *FRI* in crosses of *Arabidopsis thaliana* have been deduced from the genomic structure of alternative *FRI* alleles described in (Corre et al., (2002), *Mol. Biol. Evol.* 19, p1261).

WILD-TYPE AND POTENTIAL HYBRID PRIMARY PEPTIDES ENCODED BY EXONS 1, 2 AND 3 OF THE FRI ALLELES ASSOCIATED WITH ARABIDOPSIS THALIANA STRAINS CYR AND JEA.



- 16 -

E1, E2 and E3 refer to exons 1, 2 and 3 respectively within the *Arabidopsis thaliana* gene *Frigida*. The numbers 55, 368 and 474 refer to the positions of the variant amino acids encoded within exons 1, 2 and 3 respectively.

5 Amino acid variants encoded by and included in each exon at amino acid positions 55, 368 and 474 are indicated by the conventional three letter code. The structures of the hybrid primary peptides generated in a CYR x JEA F1 hybrid are predicted by reference to the biochemical pathway

10 validated by the experimentation above.

As described further below, once the above phenomenon is recognised and appreciated by those skilled in the art, it will be readily understood that numerous disease states

15 can be treated and plant/animals improved.

The description that follows makes use of a number of terms used in recombinant DNA technology. Unless defined otherwise, all technical and scientific terms used herein

20 have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton, et al., "Dictionary of Microbiology and Molecular Biology"

25 (2nd ed. 1994); "The Cambridge Dictionary of Science and Technology" (Walker ed., 1988); "The Glossary of Genetics" 5th Ed., Rieger, R., et al. (eds.), Springer Verlag (1991); and Hale & Marham, "The Harper Collins Dictionary of Biology" (1991). Generally, the nomenclature and the

30 laboratory procedures in plant and animal maintenance and breeding as well as recombinant DNA technology described herein are those well known and commonly employed in the art.

35 DEFINITIONS

The terms "polynucleotide", "polynucleotide sequence",

"nucleic acid sequence", and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof

10

The RNA may be mRNA. "mRNA" or "messenger RNA" is a single-stranded RNA molecule which is transcribed from DNA and which serves as a template and encodes the amino acid sequence of a protein.

15

The term "isolated" polynucleotide refers to a polynucleotide that is substantially free from other nucleic acid sequences, such as and not limited to other chromosomal and extrachromosomal DNA and RNA that normally accompany or interact with the isolated polynucleotide as found in its naturally occurring environment. Isolated polynucleotides may be purified from a host cell in which they naturally occur. Conventional nucleic acid purification methods known to skilled artisans may be used to obtain isolated polynucleotides. The term also embraces recombinant polynucleotides and chemically synthesised polynucleotides.

20

25

The term "recombinant" means, for example, that a nucleic acid sequence is made by an artificial combination of two otherwise separated segments of sequence, eg., by chemical synthesis or by the manipulation of isolated nucleic acids by genetic engineering techniques.

30

As used herein, "substantially similar" refers to nucleic acid molecules wherein changes in one or more nucleotide bases either results in no change to the amino acid

35

sequence coded or substitution of one or more amino acids does not affect the functional properties of the polypeptide encoded by the nucleotide sequence.

5 Substantially similar nucleic acid molecules may also be characterised by their ability to hybridise. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridisation under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins,
10 Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Post-hybridisation washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6 X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2 X SSC, 0.5%
15 SDS at 45°C. for 30 min, and then repeated twice with 0.2 X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2 X SSC,
20 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1 X SSC, 0.1% SDS at 65°C.

"Synthetic gene" or "synthetic nucleic acid fragments" can
25 be assembled from oligonucleotide building blocks that are chemically synthesised using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid molecules, which may then be enzymatically assembled to construct the entire
30 desired nucleic acid molecule. "Chemically synthesised", as related to a nucleic acid fragment, means that the component nucleotides were assembled in vitro. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or
35 automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal

gene expression based on optimisation of the nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those
5 codons favoured by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

"Candidate gene allele" refers to normal alleles of the
10 candidate gene sequence as well as alleles carrying variations that predispose individuals to develop hybrid vigour or hybrid debility. Accordingly, as used herein, the terms "candidate gene sequence," and "candidate gene allele" refer to the double-stranded DNA comprising the
15 gene sequence, allele, or region, as well as either of the single-stranded DNAs comprising the gene sequence, allele or region (i.e. either of the coding and non-coding strands).

20 "Candidate gene" or "gene" refers to a nucleic acid fragment, such as an mRNA fragment, that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences), in between and following (3' non-coding sequences) the coding sequence, that has the
25 potential to produce hybrid vigour or hybrid debility.

"Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" or "exogenous gene" are used herein interchangeably and refer to any gene that is not a native gene, comprising regulatory and
30 coding sequences that are not found together in nature. Accordingly, a chimeric or exogenous gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a
35 manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign-gene" refers to a

- 20 -

gene not normally found in the host organism, but that is introduced into the host organism by gene transfer.

Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a nucleotide sequence that code for a specific amino acid sequence. The term "amino acid sequence homolog" or "identity" refers to a protein with a similar amino acid sequence. One of skill will realise that the critical amino acid sequence is within a functional domain of a protein. Thus, it may be possible for a homologous protein to have less than 40% homology over the length of the amino acid sequence, but greater than 90% homology in one functional domain.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.

Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservative modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids that encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences.

Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every

position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein, which encodes a polypeptide, also describes every possible silent variation of the nucleic acid. One of skill will recognise that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid, which encodes a polypeptide, is implicit in each described sequence.

As to amino acid sequences, one of skill will recognise that a "conservatively modified variant" will result from an alteration to the coding sequence which results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.

The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
 - 2) Aspartic acid (D), Glutamic acid (E);
 - 3) Asparagine (N), Glutamine (Q);
 - 4) Arginine (R), Lysine (K);
 - 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
 - 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
- (See, e.g., Creighton, Proteins (1984)).

The term "non-conservative modified variation" refers to amino acid variation that does not involve conservative substitution. For example, the substitution of an alanine for a phenylalanine would constitute a non-conservative

modified variation.

"Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences and sequences that affect splice site selection.

"Promoter" refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or may be composed of different elements derived from different promoters found in nature, or may even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as "constitutive promoters".

"Translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence

is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency.

5 Examples of translation leader sequences have been described (Turner and Foster (1995) Mol. Biotechnol. 3:225-236). "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other

10 sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is

15 exemplified by Ingelbrecht et al. (1989) Plant Cell 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When

20 the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)"

25 refers to the RNA that is without introns and that can be translated into polypeptides by the cell. "cDNA" refers to DNA that is complementary to and derived from an mRNA template. The cDNA can be single-stranded or converted to double stranded form using, for example, the Klenow

30 fragment of DNA polymerase I. "Sense-RNA" refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular

35 processes.

The term "operably linked" refers to the association of

two or more nucleic acid fragments on a single polynucleotide so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

10 The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

15 A "protein" or "polypeptide" is a chain of amino acids arranged in a specific order determined by the coding sequence in a polynucleotide encoding the polypeptide. Each protein or polypeptide has a unique function.

20 "Altered levels" or "altered expression" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

25 "Mature protein" or the term "mature" when used in describing a protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor protein" or the term
30 "precursor" when used in describing a protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization
35 signals.

"Transformation" refers to the transfer of a nucleic acid

fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) homologous recombination and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Pat. No. 4,945,050, incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

"PCR" or "polymerase chain reaction" is well known by

those skilled in the art as a technique used for the amplification of specific DNA segments (U.S. Pat. Nos. 4,683,195 and 4,800,159).

- 5 The term "progeny" refers to any subsequent generation, including the seeds and plants therefrom, which is derived from a particular parental plant or set of parental plants.
- 10 "Regeneration" is the process of growing a plant from a plant cell (eg., plant protoplast or explant).

"Selected DNA" is a segment of DNA which has been introduced into a host genome. Preferred selected DNAs
15 will include one or more exogenous genes and the elements for expressing an exogenous gene in a host cell, for example, a promoter and a terminator. Benefit may be realised by including one or more enhancer elements with the selected DNA.

20

A "transformed cell" is a cell whose DNA has been altered by the introduction of an exogenous DNA molecule into that cell.

- 25 A "transgenic plant" is a plant or progeny of any subsequent generation derived therefrom, of a transformed plant cell or protoplast, wherein the plant DNA contains an introduced exogenous DNA molecule not originally present in a native, non-transgenic plant of the same
30 strain. The transgenic plant may additionally contain sequences which are native to the plant being transformed, but wherein the "exogenous" gene has been altered by gene technological means in order to alter the structure of the original or wild-type gene product or the level or pattern
35 of expression of the gene.

A "vector" is a DNA molecule capable of replication in a

host cell and/or to which another DNA segment can be
operatively linked so as to bring about replication of the
attached segment. A plasmid is an exemplary vector or a
DNA molecule used to carry new genes into cells. A plasmid
5 is an exemplary vector which is an independent, stable,
self-replicating piece of DNA.

As used herein, the term "genotype" means the genetic
makeup of an individual cell, cell culture, plant or
10 animal.

As used herein, the term "heterozygote" means a diploid or
polyploid individual cell or plant or animal having
different alleles (forms of a given gene) at least at one
15 locus.

As used herein, the term "heterozygous" means the presence
of different alleles (forms of a given gene) at a
particular gene locus.

20

As used herein, the term "homozygote" means an individual
cell or plant having the same alleles at one or more loci.

As used herein, the term "homozygous" means the presence
25 of identical alleles at one or more loci in homologous
chromosomal segments.

Throughout the specification, the word "comprise" and
variations of the word, such as "comprising" and
30 "comprises", means "including but not limited to" and is
not intended to exclude other additives, components,
integers or steps. By "consisting of" is meant including,
and limited to, whatever follows the phrase "consisting
of". Thus, the phrase "consisting of" indicates that the
35 listed elements are required or mandatory, and that no
other elements may be present. By "consisting essentially
of" is meant including any elements listed after the

phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially of" indicates
5 that the listed elements are required or mandatory, but that no other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

10 EXPERIMENTAL PROTOCOLS

In one of the broadest aspect of the present invention there is provided a method of identifying factors leading to hybrid vigour or hybrid debility. The term "factors" as
15 used herein refers to the presence of multiple species of mRNA or protein encoded by alleles of a candidate gene as defined herein, which either directly or indirectly leads to hybrid vigour or hybrid debility. The factors may be a result of the direct presence of one or more species of
20 mRNA or protein. Alternatively, the factors may be an indirect result of multiple species of mRNA or protein.

As discussed elsewhere, the inventor believes that hybrid vigour or hybrid debility results from the presence of one
25 or more species of "hybrid" mRNA or protein. These hybrid mRNA species or hybrid protein species can be identified using standard techniques. For example, different mRNA species can be identified using techniques such as SSCP (single standard conformational polymorphisms) or DHPLC
30 (Denaturing High-Performance Liquid Chromatography). See, for example, U.S Patent Numbers 5,795,976; and 6,453,244.

The presence of multiple species of proteins might be identified by isoelectric focussing. It would also be
35 possible to clone each of the individual mRNA species and sequence them using standard sequencing. The individual

proteins might also be sequenced. All of these methods would utilise standard techniques.

Once it has been identified that multiple species of mRNA
5 or protein are present in an animal or plant it would be possible to identify candidate genes responsible for the hybrid mRNA and/or hybrid protein.

The term "candidate gene", as defined previously, refers
10 to a nucleic acid fragment, such as an mRNA fragment, that has the potential to produce hybrid vigour or hybrid debility. The terms "hybrid vigour" or "heterosis" are used herein interchangeably and means an increase in the performance of hybrids over that of purebreds, most
15 noticeably in traits like growth rate, fertility and disease resistance. In particular the candidate genes are those genes, which are heterozygous and functional in one animal or plant and which lead to hybrid vigour. In one embodiment the alleles of each gene will comprise
20 nucleotide sequence variation in different exons of the coding sequence wherein the variations lead to amino acid sequence variation. For example, if a plant or animal comprises two alleles of gene X ie heterozygote for gene X, it satisfies the first requirement as a candidate gene
25 of the present invention. A second criterion would be sequence variation in the nucleotide sequence, which variation leads to amino acid sequence variation in any expressed protein. A third criterion would be that each allele contains sequence variation, wherein the sequence
30 variation is not found at the same position in each allele. For example, in gene X supra each allele may contain a sequence variation wherein in allele 1 the variation is at position 1, while in allele 2 the variation is at position 20. This would satisfy the 2nd
35 and 3rd criteria if the variation leads to a change in the amino acid sequence. A fourth criterion would be the variations appearing in different exons rather than merely

in different positions within the same exon.

In one embodiment, the candidate gene would have one or more nucleotide sequence variations, which code for amino acid variations, wherein the variations are found in different exons on different alleles.

The candidate genes would preferably produce mRNA of at least three species: one mRNA molecule which is identical to one allele, one that was identical to the coding sequence of the second allele and hybrid mRNA molecules that comprise a combination of exons from both alleles. Obviously depending upon the number of exons the number of different species of hybrid mRNA molecules would be numerous.

Methods of identifying candidate genes would be relatively simple. These could be identified by routine sequence analysis or Southern blot analysis of PCR amplified segments of candidate genes (see, for example, Gieselmann et al. (1989, Proc. Natl. Acad. Sci. U.S.A. 86:9436-9440). It will also be appreciated by those skilled in the art that detection of amplification in homogenous and/or closed tubes can be carried out using numerous means in the art, for example using TaqMan® hybridisation probes in the PCR reaction and measurement of fluorescence specific for the target nucleic acids once sufficient amplification has taken place. However, because of the nature and speed of the Roche Lightcycler®, the preferred method is by using real-time PCR and melting curve analysis on the Roche Lightcycler® using fluorescent labelled hybridisation oligonucleotides.

Although those skilled in the art will be aware that other similar quantitative "real-time" and homogenous nucleic acid amplification/detection systems exist such as those based on the TaqMan approach (US patent Nos 5,538,848 and

5,691,146), fluorescence polarisation assays (eg Gibson et al., Clin Chem, 1997; 43: 1336-1341), and the Invader assay (eg Agarwal P et al., Diagn Mol Pathol 2000 Sep; 9(3): 158-164; Ryan D et al, Mol Diagn 1999 Jun; 4(2): 135-144). Such systems would also be adaptable to use the invention described, enabling real-time monitoring of nucleic acid amplification and allele discrimination for detection of gene mutations and polymorphisms if appropriately designed.

10

Once a candidate gene has been identified it can then be isolated or produced synthetically to be used in other aspects of the invention. For example, a candidate gene, which is suspected of producing hybrid vigour, could be transformed into a host cell (plant or animal) and a transgenic plant or animal regenerated.

Methods for generating transgenic animal cells typically include the steps of (1) assembling a suitable DNA construct useful for inserting a specific DNA sequence into the nuclear genome of a cell; (2) transfecting the DNA construct into the cells; (3) allowing random insertion and/or homologous recombination to occur. The modification resulting from this process may be the insertion of a suitable DNA construct(s) into the target genome; deletion of DNA from the target genome; and/or mutation of the target genome.

DNA constructs can comprise a gene of interest, for example, a synthetic gene comprising exons taken from different alleles, wherein different exons comprise different sequences, as well as a variety of elements including regulatory promoters, insulators, enhancers, and repressors as well as elements for ribosomal binding to the RNA transcribed from the DNA construct. These examples are well known to a person of ordinary skill in the art and are not meant to be limiting.

Due to the effective recombinant DNA techniques available in conjunction with DNA sequences for regulatory elements and genes readily available in data bases and the commercial sector, a person of ordinary skill in the art can readily generate a DNA construct appropriate for establishing transgenic animal cells using the materials and methods described herein.

10 For example, if the entire nucleotide coding sequence for a candidate gene is not obtained in a single cDNA, genomic DNA, or other DNA, as determined, for example, by DNA sequencing or restriction endonuclease analysis, then appropriate DNA fragments (eg., restriction fragments or 15 PCR amplification products) may be recovered from several DNAs and covalently joined to one another to construct the entire coding sequence. The preferred means of covalently joining DNA fragments is by ligation using a DNA ligase enzyme, such as T4 DNA ligase. The isolated candidate 20 gene can then be incorporated into a plasmid or expression vector.

Transfection techniques for animal cells are well known to a person of ordinary skill in the art and materials and 25 methods for carrying out transfection of DNA constructs into animal cells are commercially available. Materials typically used to transfect animal cells with DNA constructs are lipophilic compounds, such as Lipofectin™ for example. Particular lipophilic compounds can be 30 induced to form liposomes for mediating transfection of the DNA construct into the cells.

Target sequences from the DNA construct can be inserted into specific regions of the nuclear genome by rational 35 design of the DNA construct. These design techniques and methods are well known to a person of ordinary skill in the art. See, for example, U.S. Patent 5,633,067; U.S.

Patent 5,612,205 and PCT publication WO93/22432, all of which are incorporated by reference herein in their entirety. Once the desired DNA sequence is inserted into the nuclear genome, the location of the insertion region
5 as well as the frequency with which the desired DNA sequence has inserted into the nuclear genome can be identified by methods well known to those skilled in the art.

10 Once the transgene is inserted into the nuclear genome of a donor cell, that cell, like other donor cells of the invention, can be used as a nuclear donor in nuclear transfer methods. The means of transferring the nucleus of a cell into an oocyte preferably involves cell fusion
15 to form a reconstituted cell.

Fusion is typically induced by application of a DC electrical pulse across the contact/fusion plane, but additional AC current may be used to assist alignment of
20 donor and recipient cells. Electrofusion produces a pulse of electricity that is sufficient to cause a transient breakdown of the plasma membrane and which is short enough that the membrane reforms rapidly. Thus, if two adjacent membranes are induced to breakdown and upon reformation
25 the lipid bilayers intermingle, small channels will open between the two cells. Due to the thermodynamic instability of such a small opening, it enlarges until the two cells become one. Reference is made to U.S. Pat. No. 4,997,384 by Prather et al., (incorporated by reference in
30 its entirety herein) for a further discussion of this process. A variety of electrofusion media can be used including eg., sucrose, mannitol, sorbitol and phosphate buffered solution.

35 Fusion can also be accomplished using Sendai virus as a fusogenic agent (Graham, Wister Inot. Symp. Monogr., 9, 19, 1969). Fusion may also be induced by exposure of the

- 34 -

cells to fusion-promoting chemicals, such as polyethylene glycol.

Preferably, the donor animal cell and oocyte are placed in
5 a 500 μ m fusion chamber and covered with 4ml of 26°C-27°C
fusion medium (0.3M mannitol, 0.1mM MgSO₄, 0.05mM CaCl₂).
The cells are then electrofused by application of a double
direct current (DC) electrical pulse of 70-100V for about
15 μ s, approximately 1s apart. After fusion, the resultant
10 fused reconstituted cells are then placed in a suitable
medium until activation, eg., TCM-199 medium.

In a preferred method of cell fusion the donor animal cell
is firstly attached to the enucleated oocyte. For
15 example, a compound is selected to attach the animal cell
to the enucleated oocyte to enable fusing of the animal
cell and enucleated oocyte membranes. The compound may be
any compound capable of agglutinating cells. The compound
may be a protein or glycoprotein capable of binding or
20 agglutinating carbohydrate. More preferably the compound
is a lectin. The lectin may be selected from the group
including Concanavalin A, Canavalin A, Ricin, soybean
lectin, lotus seed lectin and phytohemagglutinin (PHA).
Preferably the compound is PHA.

25

In one preferred embodiment, the method of electrofusion
described above also comprises a further fusion step, or
the fusion step described above comprises one donor animal
cell and two or more enucleated oocytes. The double
30 fusion method has the advantageous effect of increasing
the cytoplasmic volume of the reconstituted cell.

A reconstituted animal cell is typically activated by
electrical and/or non-electrical means before, during,
35 and/or after fusion of the nuclear donor and recipient
oocyte (See, for example, Susko-Parrish et al., U.S. Pat.
No. 5,496,720). Activation methods include:

- 35 -

- 1) Electric pulses;
 - 2) Chemically induced shock;
 - 3) Penetration by sperm;
 - 4) Increasing levels of divalent cations in
5 the oocyte by introducing divalent cations into the oocyte
cytoplasm, eg., magnesium, strontium, barium or calcium,
eg., in the form of an ionophore. Other methods of
increasing divalent cation levels include the use of
electric shock, treatment with ethanol and treatment with
10 caged chelators; and
 - 5) Reducing phosphorylation of cellular
proteins in the oocyte by known methods, eg., by the
addition of kinase inhibitors, eg., serine-threonine
kinase inhibitors, such as 6-dimethyl-aminopurine,
15 staurosporine, 2-aminopurine, and sphingosine.
Alternatively, phosphorylation of cellular proteins may be
inhibited by introduction of a phosphatase into the
oocyte, eg., phosphatase 2A and phosphatase 2B.
- 20 The activated reconstituted animal cells, or embryos, are
typically cultured in medium well known to those of
ordinary skill in the art, and include, without
limitation, TCM-199 plus 10% FSC, Tyrodes-Albumin-Lactate-
Pyruvate (TALP), Ham's F-10 plus 10% FCS, synthetic
25 oviductal fluid ("SOF"), B2, CR1aa, medium and high
potassium simplex medium ("KSOM").

The reconstituted cell may also be activated by known
methods. Such methods include, eg., culturing the
30 reconstituted cell at sub-physiological temperature, in
essence by applying a cold, or actually cool temperature
shock to the reconstituted cell. This may be most
conveniently done by culturing the reconstituted animal
cell at room temperature, which is cold relative to the
35 physiological temperature conditions to which embryos are
normally exposed. Suitable oocyte activation methods are
the subject of U.S. Pat. No. 5,496,720, to Susko-Parrish

et al., herein incorporated by reference in its entirety.

The activated reconstituted animal cells may then be cultured in a suitable in vitro culture medium until the generation of cells and cell colonies. Culture media suitable for culturing and maturation of animal embryos are well known in the art. Examples of known media, which may be used for bovine embryo culture and maintenance, include Ham's F-10 plus 10% FCS, TCM-199 plus 10% FCS, Tyrodes-Albumin-Lactate-Pyruvate (TALP), Dulbecco's Phosphate Buffered Saline (PBS), Eagle's and Whitten's media. One of the most common media used for the collection and maturation of oocytes is TCM-199, and 1 to 20% serum supplement including fetal calf serum, newborn serum, estrual cow serum, lamb serum or steer serum. A preferred maintenance medium includes TCM-199 with Earl salts, 10% FCS, 0.2mM Na pyruvate and 50µg/ml gentamicin sulphate. Any of the above may also involve co-culture with a variety of cell types such as granulosa cells, oviduct cells, BRL cells and uterine cells and STO cells.

Afterward, the cultured reconstituted animal cell or embryos are preferably washed and then placed in a suitable media, eg., TCM-199 medium containing 10% FCS contained in well plates which preferably contain a suitable confluent feeder layer. Suitable feeder layers include, by way of example, fibroblasts and epithelial cells, eg., fibroblasts and uterine epithelial cells derived from ungulates, chicken fibroblasts, murine (eg., mouse or rat) fibroblasts, STO and SI-m220 feeder cell lines, and BRL cells.

In one embodiment, the feeder cells comprise mouse embryonic fibroblasts. Preparation of a suitable fibroblast feeder layers are well known in the art.

The reconstituted animal cells are cultured on the feeder

layer until the reconstituted cells reach a size suitable for transferring to a recipient female, or for obtaining cells which may be used to produce cells or cell colonies. Preferably, these reconstituted cells will be cultured
5 until at least about 2 to 400 cells, more preferably about 4 to 128 cells, and most preferably at least about 50 cells. The culturing will be effected under suitable conditions, i.e., about 39°C. and 5% CO₂, with the culture medium changed in order to optimise growth typically about
10 every 2-5 days, preferably about every 3 days.

The methods for embryo transfer and recipient animal management in the present invention are standard procedures used in the embryo transfer industry.
15 Synchronous transfers are important for success of the present invention, ie., the stage of the nuclear transfer embryo is in synchrony with the estrus cycle of the recipient female. This advantage and how to maintain recipients are reviewed in Siedel, G. E., Jr. ("Critical
20 review of embryo transfer procedures with cattle" in Fertilization and Embryonic Development in Vitro (1981) L. Mastroianni, Jr. and J. D. Biggers, ed., Plenum Press, New York, N.Y., page 323), the contents of which are hereby incorporated by reference.

25 Briefly, blastocysts may be transferred non-surgically or surgically into the uterus of a synchronised recipient. Other medium may also be employed using techniques and media well-known to those of ordinary skill in the art. In
30 one procedure, cloned embryos are washed three times with fresh KSOM and cultured in KSOM with 0.1% BSA for 4 days and subsequently with 1% BSA for an additional 3 days, under 5% CO₂, 5% O₂ and 90% N₂ at 39°C. Embryo development is examined and graded by standard procedures known in the
35 art. Cleavage rates are recorded on day 2 and cleaved embryos are cultured further for 7 days. On day seven, blastocyst development is recorded and one or two embryos,

- 38 -

pending availability of embryos and/or animals, is transferred non-surgically into the uterus of each synchronised foster mother.

5 Foster mothers preferably are examined for pregnancy by rectal palpation or ultrasonography periodically, such as on days 40, 60, 90 and 120 of gestation. Careful observations and continuous ultrasound monitoring (monthly) preferably is made throughout pregnancy to
10 evaluate embryonic loss at various stages of gestation. Any aborted fetuses should be harvested, if possible, for DNA typing to confirm clone status as well as routine pathological examinations.

15 The reconstituted animal cell, activated reconstituted animal cell, fetus and animal produced during the steps of such method, and cells, nuclei, and other cellular components which may be harvested therefrom, are also asserted as embodiments of the present invention. It is
20 particularly preferred that the term animal produced be a viable animal.

The present invention can also be used to produce embryos, fetuses or offspring which can be used, for example, in
25 cell, tissue and organ transplantation. By taking a fetal or adult cell from an animal and using it in the cloning procedure a variety of cells, tissues and possibly organs can be obtained from cloned fetuses as they develop through organogenesis. Cells, tissues, and organs can be
30 isolated from cloned offspring as well. This process can provide a source of "materials" for many medical and veterinary therapies including cell and gene therapy. If the cells are transferred back into the animal in which the cells were derived, then immunological rejection is
35 averted. Also, because many cell types can be isolated from these clones, other methodologies such as hematopoietic chimerism can be used to avoid immunological

rejection among animals of the same species as well as between species.

In one embodiment, the candidate gene will be a plant gene
5 which is capable of producing hybrid vigour as discussed supra.

Traditionally a hybrid plant is produced by random event by crossing one elite inbred plant with one or more other,
10 genetically different and diverse, inbred plants. The crossing consists of taking the pollen from one inbred elite plant and transferring to the other elite inbred plant. The seed from crossing of two inbreds is a first generation hybrid and is called a F_1 . The F_1 of
15 commercially valuable inbreds have better yields, standability, and improvement in other important characteristics than either of the parents.

In the present invention once a candidate gene has been
20 identified it is isolated or synthesised and either subcloned into an expression vector or transformed directly into a recipient plant.

There are many methods for transforming DNA segments into
25 cells, but not all are suitable for delivering DNA to plant cells. Suitable methods for use with the current invention are believed to include virtually any method by which DNA can be introduced into a cell, such as by direct delivery of DNA such as by PEG-mediated transformation of
30 protoplasts (Omirulleh et al., 1993), by the use of meganuclease - aided transgenesis (see <http://www.cellecctis.com>) such the use of meganuclease 1-SceI, by desiccation/inhibition-mediated DNA uptake (Potrykus et al., 1985), by electroporation (U.S. Pat. No.
35 5,384,253, specifically incorporated herein by reference in its entirety), by agitation with silicon carbide fibers (Kaeppler et al., 1990; U.S. Pat. No. 5,302,523,

specifically incorporated herein by reference in its entirety; and U.S. Pat. No. 5,464,765, specifically incorporated herein by reference in its entirety), by Agrobacterium-mediated transformation (U.S. Pat. No. 5,591,616 and U.S. Pat. No. 5,563,055; both specifically incorporated herein by reference) and by acceleration of DNA coated particles (U.S. Pat. No. 5,550,318; U.S. Pat. No. 5,538,877; and U.S. Pat. No. 5,538,880; each specifically incorporated herein by reference in its entirety), etc. Through the application of techniques such as these, plant cells may be stably transformed, and these cells developed into transgenic plants. In certain embodiments, acceleration methods are preferred and include, for example, microprojectile bombardment and the like.

Where one wishes to introduce candidate gene DNA by means of electroporation, it is contemplated that the method of Krzyzek et al. (U.S. Pat. No. 5,384,253, incorporated herein by reference in its entirety) will be particularly advantageous. In this method, certain cell wall-degrading enzymes, such as pectin-degrading enzymes, are employed to render the target recipient cells more susceptible to transformation by electroporation than untreated cells. Alternatively, recipient cells are made more susceptible to transformation by mechanical wounding.

To effect transformation by electroporation, one may employ either friable tissues, such as a suspension culture of cells or embryogenic callus or alternatively one may transform immature embryos or other organised tissue directly. In this technique, one would partially degrade the cell walls of the chosen cells by exposing them to pectin-degrading enzymes (pectolyases) or mechanically wounding in a controlled manner. Examples of some species which have been transformed by electroporation of intact cells include maize (U.S. Pat.

No. 5,384,253; D'Halluin et al., 1992; Rhodes et al., 1995), wheat (Zhou et al., 1993), tomato (Hou and Lin, 1996), soybean (Christou et al., 1987), and tobacco (Lee et al., 1989).

5

One may also employ protoplasts for electroporation transformation of plants (Bates, 1994; Lazzeri, 1995). For example, the generation of transgenic soybean plants by electroporation of cotyledon-derived protoplasts is described by Dhir and Widholm in Intl. Patent Appl. Publ. No. WO 9217598 (specifically incorporated herein by reference). Other examples of species for which protoplast transformation has been described include barley (Lazzeri, 1995), sorghum (Battraw et al., 1991), maize (Bhattacharjee et al., 1997), wheat (He et al., 1994), tomato (Tsukada, 1989), and soybean (Dhir et al., 1992).

A preferred method for delivering transforming candidate gene DNA segments to plant cells in accordance with the invention is microprojectile bombardment (U.S. Pat. No. 5,550,318; U.S. Pat. No. 5,538,880; U.S. Pat. No. 5,610,042; and PCT Application WO 94/09699; each of which is specifically incorporated herein by reference in its entirety). In this method, particles may be coated with nucleic acids and delivered into cells by a propelling force. Exemplary particles include those comprised of tungsten, platinum, and preferably, gold. It is contemplated that in some instances candidate gene DNA precipitation onto metal particles would not be necessary for DNA delivery to a recipient cell using microprojectile bombardment. However, it is contemplated that particles may contain DNA rather than be coated with DNA. Hence, it is proposed that DNA-coated particles may increase the level of DNA delivery via particle bombardment but are not, in and of themselves, necessary.

An illustrative embodiment of a method for delivering DNA

into plant cells by acceleration is the Biolistics Particle Delivery System, which can be used to propel particles coated with DNA or cells through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with plant cells cultured in suspension. The screen disperses the particles so that they are not delivered to the recipient cells in large aggregates. It is believed that a screen intervening between the projectile apparatus and the cells to be bombarded reduces the size of projectiles aggregate and may contribute to a higher frequency of transformation by reducing the damage inflicted on the recipient cells by projectiles that are too large.

Microprojectile bombardment techniques are widely applicable, and may be used to transform virtually any plant species. Examples of species for which have been transformed by microprojectile bombardment include monocot species such as maize (PCT Application WO 95/06128), barley (Ritala et al., 1994; Hensgens et al., 1993), wheat (U.S. Pat. No. 5,563,055, specifically incorporated herein by reference in its entirety), rice (Hensgens et al., 1993), oat (Torbet et al., 1995; Torbet et al., 1998), rye (Hensgens et al., 1993), sugarcane (Bower et al., 1992), and sorghum (Casa et al., 1993; Hagio et al., 1991); as well as a number of dicots including tobacco (Tomes et al., 1990; Buising and Benbow, 1994), soybean (U.S. Pat. No. 5,322,783, specifically incorporated herein by reference in its entirety), sunflower (Knittel et al. 1994), peanut (Singsit et al., 1997), cotton (McCabe and Martinell, 1993), tomato (VanEck et al. 1995), and legumes in general (U.S. Pat. No. 5,563,055, specifically incorporated herein by reference in its entirety).

For the bombardment, cells in suspension are concentrated on filters or solid culture medium. Alternatively, immature embryos or other target cells may be arranged on

solid culture medium. The cells to be bombarded are positioned at an appropriate distance below the macroprojectile stopping plate. If desired, one or more screens may be positioned between the acceleration device
5 and the cells to be bombarded.

Agrobacterium-mediated transfer is a widely applicable system for introducing genes into plant cells because the DNA can be introduced into whole plant tissues, thereby
10 bypassing the need for regeneration of an intact plant from a protoplast. The use of Agrobacterium-mediated plant integrating vectors to introduce DNA into plant cells is well known in the art. See, for example, the methods described by Fraley et al., (1985), Rogers et al., (1987)
15 and U.S. Pat. No. 5,563,055, specifically incorporated herein by reference in its entirety.

Agrobacterium-mediated transformation is most efficient in dicotyledonous plants and is the preferable method for
20 transformation of dicots, including Arabidopsis, tobacco, tomato, and potato. Indeed, while Agrobacterium-mediated transformation has been routinely used with dicotyledonous plants for a number of years, it has only recently become applicable to monocotyledonous plants. Advances in
25 Agrobacterium-mediated transformation techniques have now made the technique applicable to nearly all monocotyledonous plants. For example, Agrobacterium-mediated transformation techniques have now been applied to rice (Hiei et al., 1997; Zhang et al., 1997; U.S. Pat.
30 No. 5,591,616, specifically incorporated herein by reference in its entirety), wheat (McCormac et al., 1998), barley (Tingay et al., 1997; McCormac et al., 1998), and maize (Ishidia et al., 1996).

35 Modern Agrobacterium transformation vectors are capable of replication in *E. coli* as well as Agrobacterium, allowing for convenient manipulations as described (Klee et al.,

1985). Moreover, recent technological advances in vectors for *Agrobacterium*-mediated gene transfer have improved the arrangement of genes and restriction sites in the vectors to facilitate the construction of vectors capable of
5 expressing various polypeptide coding genes. The vectors described (Rogers et al., 1987) have convenient multi-linker regions flanked by a promoter and a polyadenylation site for direct expression of inserted polypeptide coding genes and are suitable for present purposes. In addition,
10 *Agrobacterium* containing both armed and disarmed Ti genes can be used for the transformations. In those plant strains where *Agrobacterium*-mediated transformation is efficient, it is the method of choice because of the facile and defined nature of the gene transfer.

15 Transformation of plant protoplasts can be achieved using methods based on calcium phosphate precipitation, polyethylene glycol treatment, electroporation, and combinations of these treatments (see, e.g., Potrykus et al., 1985; Lorz et al., 1985; Omirulleh et al., 1993;
20 Fromm et al., 1986; Uchimiya et al., 1986; Callis et al., 1987; Marcotte et al., 1988).

Application of these systems to different plant strains
25 depends upon the ability to regenerate that particular plant strain from protoplasts. Illustrative methods for the regeneration of cereals from protoplasts have been described (Fujimara et al., 1985; Toriyama et al., 1986; Yamada et al., 1986; Abdullah et al., 1986; Omirulleh et al., 1993 and U.S. Pat. No. 5,508,184; each specifically
30 incorporated herein by reference in its entirety).

Examples of the use of direct uptake transformation of cereal protoplasts include transformation of rice (Ghosh-Biswas et al., 1994), sorghum (Battraw and Hall, 1991),
35 barley (Lazerri, 1995), oat (Zheng and Edwards, 1990) and maize (Omirulleh et al., 1993).

To transform plant strains that cannot be successfully regenerated from protoplasts, other ways to introduce DNA into intact cells or tissues can be utilised. For example, regeneration of cereals from immature embryos or explants can be effected as described (Vasil, 1989). Also, silicon carbide fiber-mediated transformation may be used with or without protoplasting (Kaeppler, 1990; Kaeppler et al., 1992; U.S. Pat. No. 5,563,055, specifically incorporated herein by reference in its entirety). Transformation with this technique is accomplished by agitating silicon carbide fibers together with cells in a DNA solution. DNA passively enters as the cells are punctured. This technique has been used successfully with, for example, the monocot cereals maize (PCT Application WO 95/06128, specifically incorporated herein by reference in its entirety; Thompson, 1995) and rice (Nagatani, 1997).

Optimisation of Microprojectile Bombardment

For microprojectile bombardment transformation in accordance with the current invention, both physical and biological parameters may be optimised. Physical factors are those that involve manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps involved in manipulation of cells before and immediately after bombardment, such as the osmotic adjustment of target cells to help alleviate the trauma associated with bombardment, the orientation of an immature embryo or other target tissue relative to the particle trajectory, and also the nature of the transforming DNA, such as linearized DNA or intact supercoiled plasmids. It is believed that pre-bombardment manipulations are especially important for successful transformation of immature embryos.

- 46 -

Accordingly, it is contemplated that one may wish to adjust various of the bombardment parameters in small scale studies to fully optimise the conditions. One may particularly wish to adjust physical parameters such as DNA concentration, gap distance, flight distance, tissue distance, and helium pressure. It is further contemplated that the grade of helium may effect transformation efficiency. For example, differences in transformation efficiencies may be witnessed between bombardments using industrial grade (99.99% pure) or ultra pure helium (99.999% pure), although it is not currently clear which is more advantageous for use in bombardment. One may also optimize the trauma reduction factors (TRFs) by modifying conditions which influence the physiological state of the recipient cells and which may therefore influence transformation and integration efficiencies. For example, the osmotic state, tissue hydration and the subculture stage or cell cycle of the recipient cells may be adjusted for optimum transformation.

20

Both physical and biological parameters for bombardment may be addressed for further optimisation of ballistic transformation. Physical factors are those that involve manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps involved in manipulation of cells immediately before and after bombardment. The pre-bombardment culturing conditions, such as osmotic environment, the bombardment parameters, and the plasmid configuration have been adjusted to yield the maximum numbers of stable transformants.

30

(i) Physical Parameters

35

1. Gap Distance

The variable nest (macro holder) can be adjusted to vary the distance between the rupture disk and the macroprojectile, i.e., the gap distance. This distance can be varied from 0 to 2 cm. The predicted effects of a shorter gap are an increase of velocity of both the macro- and microprojectiles, an increased shock wave (which leads to tissue splattering and increased tissue trauma), and deeper penetration of microprojectiles. Longer gap distances would have the opposite effects but may increase viability and therefore the total number of recovered stable transformants.

2. Flight Distance

The fixed nest (contained within the variable nest) can be varied between 0.5 and 2.25 cm in predetermined 0.5 cm increments by the placement of spacer rings to adjust the flight path traversed by the macroprojectile. Short flight paths allow for greater stability of the macroprojectile in flight but reduce the overall velocity of the microprojectiles. Increased stability in flight increases, for example, the number of centered GUS foci. Greater flight distances (up to some point) increase velocity but also increase instability in flight. Based on observations, it is recommended that bombardments typically be done with a flight path length of about 1.0 cm to 1.5 cm.

3. Tissue Distance

Placement of tissue within the gun chamber can have significant effects on microprojectile penetration. Increasing the flight path of the microprojectiles will decrease velocity and trauma associated with the shock wave. A decrease in velocity also will result in shallower penetration of the microprojectiles.

4. Helium Pressure

By manipulation of the type and number of rupture disks, pressure can be varied between 400 and 2000 psi within the gas acceleration tube. Optimum pressure for stable transformation has been determined to be between 1000 and 1200 psi.

5. Coating of Microprojectiles.

10

For microprojectile bombardment, one will attach (i.e. "coat") DNA to the microprojectiles such that it is delivered to recipient cells in a form suitable for transformation thereof. In this respect, at least some of the transforming DNA must be available to the target cell for transformation to occur, while at the same time during delivery the DNA must be attached to the microprojectile. Therefore, availability of the transforming DNA from the microprojectile may comprise the physical reversal of bonds between transforming DNA and the microprojectile following delivery of the microprojectile to the target cell. This need not be the case, however, as availability to a target cell may occur as a result of breakage of unbound segments of DNA or of other molecules which comprise the physical attachment to the microprojectile. Availability may further occur as a result of breakage of bonds between the transforming DNA and other molecules, which are either directly or indirectly attached to the microprojectile. It further is contemplated that transformation of a target cell may occur by way of direct recombination between the transforming DNA and the genomic DNA of the recipient cell. Therefore, as used herein, a "coated" microprojectile will be one which is capable of being used to transform a target cell, in that the transforming DNA will be delivered to the target cell, yet will be accessible to the target cell such that transformation may occur.

Any technique for coating microprojectiles which allows for delivery of transforming DNA to the target cells may be used. Methods for coating microprojectiles which have
5 been demonstrated to work well with the current invention have been specifically disclosed herein. DNA may be bound to microprojectile particles using alternative techniques,
10 however. For example, particles may be coated with streptavidin and DNA end labelled with long chain thiol cleavable biotinylated nucleotide chains. The DNA adheres to the particles due to the streptavidin-biotin
interaction, but is released in the cell by reduction of the thiol linkage through reducing agents present in the
cell.

15

Alternatively, particles may be prepared by functionalising the surface of a gold oxide particle, providing free amine groups. DNA, having a strong negative charge, binds to the functionalised particles.

20

Furthermore, charged particles may be deposited in controlled arrays on the surface of mylar flyer disks used in the PDS-1000 Biolistics device, thereby facilitating controlled distribution of particles delivered to target
tissue.

25

As disclosed above, it further is proposed, that the concentration of DNA used to coat microprojectiles may influence the recovery of transformants containing a single copy of the transgene. For example, a lower
30 concentration of DNA may not necessarily change the efficiency of the transformation, but may instead increase the proportion of single copy insertion events. In this regard, approximately 1 ng to 2000 ng of transforming DNA may be used per each 1.8 mg of starting microprojectiles.
35 In other embodiments of the invention, approximately 2.5 ng to 1000 ng, 2.5 ng to 750 ng, 2.5 ng to 500 ng, 2.5 ng to 250 ng, 2.5 ng to 100 or 2.5 ng to 50 ng of

transforming DNA may be used per each 1.8 mg of starting microprojectiles.

Various other methods may also be used to increase
5 transformation efficiency and/or increase the relative
proportion of low-copy transformation events. For example,
the inventors contemplate end-modifying transforming DNA
with alkaline phosphatase or an agent which will blunt DNA
ends prior to transformation. Still further, an inert
10 carrier DNA may be included with the transforming DNA,
thereby lowering the effective transforming DNA
concentration without lowering the overall amount of DNA
used. These techniques are further described in U.S.
patent application Ser. No. 08/995,451, filed Dec. 22,
15 1997, the disclosure of which is specifically incorporated
herein by reference in its entirety.

(ii) Biological Parameters

20 Culturing conditions and other factors can influence the
physiological state of the target cells and may have
profound effects on transformation and integration
efficiencies. First, the act of bombardment could
stimulate the production of ethylene which could lead to
25 senescence of the tissue. The addition of antiethylene
compounds could increase transformation efficiencies.
Second, it is proposed that certain points in the cell
cycle may be more appropriate for integration of
introduced DNA. Hence synchronisation of cell cultures may
30 enhance the frequency of production of transformants. For
example, synchronisation may be achieved using cold
treatment, amino acid starvation, or other cell cycle-
arresting agents. Third, the degree of tissue hydration
also may contribute to the amount of trauma associated
35 with bombardment as well as the ability of the
microprojectiles to penetrate cell walls.

The position and orientation of an embryo or other target tissue relative to the particle trajectory may also be important. For example, the PDS-1000 biolistics device does not produce a uniform spread of particles over the surface of a target petri dish. The velocity of particles in the centre of the plate is higher than the particle velocity at further distances from the centre of the petri dish. Therefore, it is advantageous to situate target tissue on the petri dish such as to avoid the centre of the dish, referred to by some as the "zone of death." Furthermore, orientation of the target tissue with regard to the trajectory of targets also can be important. It is contemplated that it is desirable to orient the tissue most likely to regenerate a plant toward the particle stream. For example, the scutellum of an immature embryo comprises the cells of greatest embryogenic potential and therefore should be oriented toward the particle stream.

It also has been reported that slightly plasmolyzed yeast cells allow increased transformation efficiencies (Armaleo et al., 1990). It was hypothesised that the altered osmotic state of the cells helped to reduce trauma associated with the penetration of the microprojectile. Additionally, the growth and cell cycle stage may be important with respect to transformation.

1. Osmotic Adjustment

It has been suggested that osmotic pre-treatment could potentially reduce bombardment associated injury as a result of the decreased turgor pressure of the plasmolyzed cell. In a previous study, the number of cells transiently expressing GUS increased following subculture into both fresh medium and osmotically adjusted medium (PCT Application WO 95/06128, specifically incorporated herein by reference in its entirety). Pretreatment times of 90 minutes showed higher numbers of GUS expressing foci than

- 52 -

shorter times. Cells incubated in 500 mOSM/kg medium for 90 minutes showed an approximately 3.5 fold increase in transient GUS foci than the control. Preferably, immature embryos are precultured for 4-5 hours prior to bombardment on culture medium containing 12% sucrose. A second culture on 12% sucrose is performed for 16-24 hours following bombardment. Alternatively, type II cells are pretreated on 0.2M mannitol for 3-4 hours prior to bombardment. It is contemplated that pretreatment of cells with other osmotically active solutes for a period of 1-6 hours may also be desirable.

2. Plasmid Configuration

In some instances, it will be desirable to deliver candidate gene DNA to cells that do not contain DNA sequences necessary for maintenance of the plasmid vector in the bacterial host, eg., *E. coli*, such as antibiotic resistance genes, including but not limited to ampicillin, kanamycin, and tetracycline resistance, and prokaryotic origins of DNA replication. In such case, a DNA fragment containing the transforming DNA may be purified prior to transformation. An exemplary method of purification is gel electrophoresis on a 1.2% low melting temperature agarose gel, followed by recovery from the agarose gel by melting gel slices in a 6-10 fold excess of Tris-EDTA buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 70°C.-72°C); frozen and thawed (37°C); and the agarose pelleted by centrifugation. A Qiagen Q-100 column then may be used for purification of DNA. For efficient recovery of DNA, the flow rate of the column may be adjusted to 40 ml/hr.

Isolated DNA fragments can be recovered from agarose gels using a variety of electroelution techniques, enzyme digestion of the agarose, or binding of DNA to glass beads (e.g., Gene Clean). In addition, HPLC and/or use of magnetic particles may be used to isolate DNA fragments.

As an alternative to isolation of DNA fragments, a plasmid vector can be digested with a restriction enzyme and this DNA delivered to maize cells without prior purification of the expression cassette fragment.

5

Tissue culture requires media and controlled environments. "Media" refers to the numerous nutrient mixtures that are used to grow cells in vitro, that is, outside of the intact living organism. The medium usually is a suspension
10 of various categories of ingredients (salts, amino acids, growth regulators, sugars, buffers) that are required for growth of most cell types. However, each specific cell type requires a specific range of ingredient proportions for growth, and an even more specific range of formulas
15 for optimum growth. Rate of cell growth also will vary among cultures initiated with the array of media that permit growth of that cell type.

Nutrient media is prepared as a liquid, but this may be
20 solidified by adding the liquid to materials capable of providing a solid support. Agar is most commonly used for this purpose. Bactoagar, Hazelton agar, Gelrite, and Gelgro are specific types of solid support that are suitable for growth of plant cells in tissue culture.

25

Some cell types will grow and divide either in liquid suspension or on solid media. As disclosed herein, maize cells will grow in suspension or on solid medium, but regeneration of plants from suspension cultures requires
30 transfer from liquid to solid media at some point in development. The type and extent of differentiation of cells in culture will be affected not only by the type of media used and by the environment, for example, pH, but also by whether media is solid or liquid.

35

Recipient cell targets include, but are not limited to, meristem cells, including the shoot apex (U.S. Pat. No.

5,736,369), Type I, Type II, and Type III callus, immature embryos and gametic cells such as microspores, pollen, sperm and egg cells. It is contemplated that any cell from which a fertile plant may be regenerated is useful as a recipient cell. Type I, Type II, and Type III callus may be initiated from tissue sources including, but not limited to, immature embryos, seedling apical meristems, microspores and the like. Those cells which are capable of proliferating as callus are also recipient cells for genetic transformation. The present invention provides techniques for transforming immature embryos and subsequent regeneration of fertile transgenic plants. Transformation of immature embryos obviates the need for long term development of recipient cell cultures. Pollen, as well as its precursor cells, microspores, may be capable of functioning as recipient cells for genetic transformation, or as vectors to carry foreign DNA for incorporation during fertilisation. Direct pollen transformation would obviate the need for cell culture. Meristematic cells (i.e., plant cells capable of continual cell division and characterised by an undifferentiated cytological appearance, normally found at growing points or tissues in plants such as root tips, stem apices, lateral buds, etc.) may represent another type of recipient plant cell. Because of their undifferentiated growth and capacity for organ differentiation and totipotency, a single transformed meristematic cell could be recovered as a whole transformed plant. In fact, it is proposed that embryogenic suspension cultures may be an *in vitro* meristematic cell system, retaining an ability for continued cell division in an undifferentiated state, controlled by the media environment.

Cultured plant cells that can serve as recipient cells for transforming with desired DNA segments may be any plant cells including corn cells, and more specifically, cells from *Zea mays* L. Somatic cells are of various types.

Embryogenic cells are one example of somatic cells which may be induced to regenerate a plant through embryo formation. Non-embryogenic cells are those which typically will not respond in such a fashion. An example of non-embryogenic cells are certain Black Mexican Sweet (BMS) corn cells.

The development of embryogenic calli and suspension cultures useful in the context of the present invention, eg., as recipient cells for transformation, has been described in U.S. Pat. No. 5,134,074; and U.S. Pat. No. 5,489,520; each of which is incorporated herein by reference in its entirety.

Certain techniques may be used that enrich recipient cells within a cell population. For example, Type II callus development, followed by manual selection and culture of friable, embryogenic tissue, generally results in an enrichment of recipient cells for use in, microprojectile transformation. Suspension culturing, particularly using the media disclosed herein, may improve the ratio of recipient to non-recipient cells in any given population. Manual selection techniques which can be employed to select recipient cells may include, eg., assessing cell morphology and differentiation, or may use various physical or biological means of selection. Cryopreservation is also a possible method of selecting for recipient cells.

Manual selection of recipient cells, eg., by selecting embryogenic cells from the surface of a Type II callus, is one means that may be used in an attempt to enrich for recipient cells prior to culturing (whether cultured on solid media or in suspension). The preferred cells may be those located at the surface of a cell cluster, and may further be identifiable by their lack of differentiation, their size and dense cytoplasm. The preferred cells will

generally be those cells which are less differentiated, or not yet committed to differentiation. Thus, one may wish to identify and select those cells which are cytoplasmically dense, relatively unvacuolated with a high nucleus to cytoplasm ratio (e.g., determined by cytological observations), small in size (e.g., 10-20 μ m), and capable of sustained divisions and somatic proembryo formation.

10 It is proposed that other means for identifying such cells may also be employed. For example, through the use of dyes, such as Evan's blue, which are excluded by cells with relatively non-permeable membranes, such as embryogenic cells, and taken up by relatively differentiated cells such as root-like cells and snake cells (so-called due to their snake-like appearance).

Other possible means of identifying recipient cells include the use of isozyme markers of embryogenic cells, such as glutamate dehydrogenase, which can be detected by cytochemical stains (Fransz et al., 1989). However, it is cautioned that the use of isozyme markers including glutamate dehydrogenase may lead to some degree of false positives from non-embryogenic cells such as rooty cells which nonetheless have a relatively high metabolic activity.

In one embodiment, a hybrid mRNA molecule derived from the candidate gene, or a hybrid protein derived from the hybrid mRNA molecule, rather than producing hybrid vigour, will overcome, treat or at least alleviate the symptoms of disease. It will be appreciated by those skilled in the field that the experimental protocols outline above may be used to bring about this outcome.

35

Generally, the terms "treating," "treatment" and the like are used herein to mean affecting an individual or

subject, their tissue or cells to obtain a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing a disease or sign or symptom thereof, and/or
5 may be therapeutic in terms of a partial or complete cure of disease. "Treating" as used herein covers any treatment of, or prevention of disease in a plant or animal, and includes: (a) preventing the disease from occurring in a plant or animal that may be predisposed to
10 the disease, but has not yet been diagnosed as having them; (b) inhibiting the disease, ie., arresting its development; or (c) relieving or ameliorating the symptoms of the disease, ie., cause regression of the symptoms of the disease; or (d) enhancing the well-being, health or
15 longevity of an animal or plant.

Once a plant or animal afflicted with a disease has been diagnosed and a candidate gene, or combination of genes, has been identified then these genes or gene products may
20 be administered to the plant or animal either using the techniques described above with respect to hybrid vigour or using standard medical or agricultural techniques.

The terms "administration," "administering," and
25 "administered" are used herein interchangeably. For example, the candidate gene products may be administered orally including sublingual, topically, or parenterally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and
30 vehicles. The term parenteral as used herein includes subcutaneous injections, aerosol, intravenous, intramuscular, intrathecal, intracranial, injection or infusion techniques or rectal or vaginally.

35 In another aspect of the present invention the hybrid proteins can be isolated and further studied to determine whether or not they have an effect on HV or HD. For

example, alteration in the immunogenicity of a hybrid protein can be determined by subjecting the amino acid sequence of the hybrid protein to a series of proteomic and physicochemical analyses. Many different analytical and computerised programs have been compiled. An example of a suite of programs that may be used to compare the immunogenicity of hybrid proteins to each of the parental wild-types is offered by ePitopes Informatics. For references see <http://www.epitope-informatics.com/References.htm#ModernAb>

10

Although not exclusive, the physicochemical properties are determined using the following investigative programs:

- i/ protein antigenicity prediction algorithms.
- 15 ii/ protein hydrophobicity algorithms.
- iii/ protein hydrophilicity algorithms.
- iv/ protein flexibility prediction algorithm.
- v/ protein secondary structure algorithms.

20 The values of these physicochemical properties of a protein or are well known to anyone skilled in the art. Structural and functional differences between hybrid proteins and wild-type proteins in vitro are determined by interrogation of their amino acid sequences using a series of freely available analytical programs. The potential structural or functional features of hybrid proteins compared to wild-type proteins are evaluated using any of a wide range of proteomic analytical software including those available through NCBI databases, EMBOSS databases or those available through the GeneCards website of the Weizmann Institute of Science

25
30 <http://bioinfo.weizmann.ac.il/cards/index.shtml>

The invention will now be further described by way of reference only to the following non-limiting examples. It should be understood, however, that the examples following are illustrative only, and should not be taken in any way

35

as a restriction on the generality of the invention described above. In particular, while the invention has been described in detail above, in relation to the identification of candidate genes using *DNMT2* alleles, it will be clearly understood that the findings herein are not limited to this gene or alleles.

EXAMPLE 1 IDENTIFICATION OF A NOVEL BIOCHEMICAL
PATHWAY THAT FORMS HYBRID mRNA MOLECULES
IN HETEROZYGOUS OFFSPRING

Two allelic forms of the gene *DNMT2* have been described (Franchina et al., (2001), *Hum. Hered.*, 52, p210). *DNMT2* encodes an enzyme, which is involved in the process of DNA methylation. One of the alleles *DNMT2I* includes the nucleotides G in position 104 of exon 2 and C in position 50 of exon 4. The alternative allele, *DNMT2II* includes nucleotides A and T in these positions respectively. Thus the difference in the sequence of DNA within exons 2 and 4 between each of the two allelic forms of *DNMT2* permits the allelic origin of exons 2 and 4 in a final mRNA molecule to be determined. These findings were used to test whether hybrid forms of mRNA can be formed in heterozygous offspring by incorporation of exons from each allele into the same mature mRNA molecule, thereby generating novel polypeptide or protein molecules unique to heterozygous offspring.

In order to determine whether and how efficiently exons or parts thereof from each *DNMT2* allele can be incorporated into the same mature RNA molecule after splicing of the primary transcript, mRNA was isolated from the peripheral blood leukocytes (PBL) of two subjects III 1 and III 2, who were confirmed by segregation studies to be heterozygous for the two allelic forms of *DNMT2* (see Franchina et al., *supra*).

The mRNA was subjected to RT-PCR using primers, which amplified a region of cDNA of approximately 480bp that included exons 2 and 4 from *DNMT2*. The RT-PCR products of approximately 480bp in length from subjects III 1 and III 2 were cloned and a series of clones from each RT-PCR product were sequenced.

As shown in Table 1, inserts from 13 of 15 clones sequenced from subject III 1 reflected bi-allelic expression of *DNMT2* and as expected, cis-assembly of exons 2 and 4 in the mature mRNA molecule. One of the clones however, included a splice product that comprised exon 2 from the *DNMT2 I* allele and exon 4 from the *DNMT2 II* allele. A further clone comprised exon 2 from the *DNMT2 II* allele as well as exon 4 from the *DNMT2 I* allele. To assess the reproducibility of these findings and to exclude the possibility that the two apparent hybrid mRNA molecules found in subject III 1 were consequential to some form of mitotic recombinational event, mRNA species were examined similarly from the PBL of subject III 2.

As shown in Table 1, 11 of 14 clones contained inserts, which reflected bi-allelic expression of *DNMT2* and cis-exonic assembly. The structure of a further 3 clones, however, indicated that hybrid mRNA molecules had been assembled. Two of them included exon 2 from the *DNMT2 II* allele and exon 4 from the *DNMT2 I* allele. The sequence of a further clone revealed that a spliced mRNA molecule had been assembled by incorporation of exon 2 from the *DNMT2 I* allele and exon 4 from the *DNMT2 II* allele.

mRNA was then isolated from the PBL of a further two subjects, II 3 and II 4 (Franchina *et al.*, *supra*) who were confirmed to be homozygous for each of the two alternative allelic forms of *DNMT2*. An *in vitro* prepared mixture of equal quantities of mRNA from subjects II 3 and II 4 was treated in the same way as mRNA from subjects III 1 and

III 2 used to exclude the possibility that the hybrid mRNA
DNMT2 molecules found in the PBL of subjects III 1 and III
2 may have been generated in vitro due to template
switching in the PCR stage of the RT-PCR due to the
5 formation of truncated reverse transcripts. As shown in
Table 1, no hybrid mRNA molecules were found by reference
to the sequence of inserts from 13 clones. Taken together,
these findings establish that almost 20% of all spliced
DNMT2 mRNA molecules comprise hybrid forms.

- 62 -

TABLE 1

5 DISTRIBUTION OF SPLICED DNMT2 MRNA MOLECULES IN PERIPHERAL BLOOD LEUKOCYTES ACCORDING TO THE NUCLEOTIDES PRESENT AT THE POLYMORPHIC POSITIONS WITHIN EXONS 2 AND 4.

DNMT2 transcripts			Subject		
nt 104 of exon 2	nt 50 of exon 4	III 1	III 2	Mix*	
G	C	5	5	8	
A	T	8	6	5	
G	T	1	1	0	
A	C	1	2	0	

10 Note: The genotypes *DNMT2 I/II* were confirmed in subjects III 1, III 2, and *DNMT2 I/I* and *DNMT2 II/II* in subjects II 3 and II 4 respectively by pedigree analysis (see Franchina and Kay, Hum. Hered. 52,210 (2001)).

15 *A mixture of mRNA from the homozygous *DNMT2 I* and *DNMT2 II* parents of subjects III 1, III 2, (II 3 and II 4) was also subjected to RT-PCR and the products cloned and sequenced. No inserts were found which specified G-T or A-C spliced *DNMT2* mRNA molecules in the mixed mRNA sample. These results confirm the presence of an *in vivo* primary transcript splicing system involved in trans-exonic, bi-
20 allelic assembly of mRNA molecules.

EXAMPLE 2 OSTEOPOROSIS AS A MODEL OF HV IN HUMANS

Osteoporosis is a bone disorder suffered by almost 40% of post-menopausal women. It is caused by increased bone
5 resorption by osteoclasts resulting in decreased bone density and increased susceptibility to bone fractures. Calcitonin is used to treat osteoporosis because it binds to the calcitonin receptor on osteoclasts and reduces their ability to cause bone decay.

10

Taboulet *et al.*, (1998), *Hum.Mol.Genet.*7, p2129 have shown that subjects who are heterozygous for wild-type calcitonin receptor alleles, as shown in Table 2, have higher bone density and a reduced risk of bone fractures
15 compared to subjects who are homozygous for the same wild type alleles.

Table 2 shows the exon location of nucleotide changes that encode different amino acids in different allelic forms of
20 the calcitonin receptor. These coding sequence variations were retrieved from NCBI databases. As shown in the Table 2, exon 1 may encode either leucine or arginine at amino acid position 126 whereas proline or leucine may be encoded by nucleotide differences within exon 9 at amino
25 acid position 447. The distribution of nucleotide sequence differences which encode the alternative amino acids at positions 126 and 447 of the calcitonin receptor satisfy the structural criteria required to enable the formation of novel or hybrid forms of calcitonin receptor in
30 subjects who are heterozygous for different allelic forms of the calcitonin receptor gene.

- 64 -

TABLE 2EXON LOCATION OF NUCLEOTIDE CHANGES WHICH ENCODE AMINO
ACID DIFFERENCES IN ALTERNATIVE CALCITONIN RECEPTOR5 ALLELES

	Amino acid position	Exon	Amino acid alternative
	126	1	(L) Leucine
10	126	1	(R) Arginine
	447	9	(P) Proline
	447	9	(L) Leucine

15

enzyme in subjects who are heterozygous for two different mutant forms of the ASL gene.

EXAMPLE 4 CYSTINURIA AS A MODEL OF HV FOR NEW
5 BIOCHEMICAL PATHWAY

Cystinuria is a human disorder characterised by impaired renal absorption of cystine and other amino acids. One form of cystinuria (referred to as non-type 1 cystinuria) has been shown to be caused by mutations in a gene designated SLC7A9. Homozygosity for mutant forms of SLC7A9 such as G105R, V170M and A354T results in a marked reduction in cystine reabsorption. As shown by Font et al., (2001), *Hum.Mol.Genet.*10, 305, heterozygosity for each of these mutant forms of SLC7A9 results in dramatic restoration of cystine reabsorption. In keeping with the model nucleotide changes within SLC7A9 which result in generation of the mutant alleles G105R, V170M and A354T, reside in exons 4, 5 and 10 respectively. The localisation of the nucleotide changes which encode each of the three mutant forms of SLC7A9 satisfy the structural requirements needed to synthesise normally active SLC7A9 in subjects who are heterozygous for any two of the three mutant forms of SLC7A9 shown above.

25
EXAMPLE 5 LONGEVITY AS A MAMMALIAN HV MODEL FOR NEW
 BIOCHEMICAL PATHWAY

The *Klotho* gene (*KL*) encodes a putative type 1 membrane protein as well as a secreted form. Although the secreted form is expressed in many different tissues such as brain, placenta, kidney, prostate and small intestine its precise function remains uncertain. It is recognised however that *KL* influences longevity because mice that have defective forms of a homologous gene show symptoms resembling human aging including atherosclerosis, emphysema and infertility. Evidence also indicates that *Klotho* reduces

blood pressure, a factor known to influence mortality (see Arking *et al.*, (2002), *Proc Natl. Acad. Sci. USA* 99, p856).

- 5 In keeping with a human model of HV, a recent study has shown that heterozygous *Klotho* subjects are at less risk of early death compared to homozygous subjects (Arking *et al.*, (2005), *Circ. Res.* 96, p412.
- 10 Table 3 details the exonic location of nucleotide changes that encode different amino acids in alternative allelic forms of *Klotho* gene products. Coding region sequence variations were retrieved from NCBI databases. As shown in
15 amino acid position 15 and either valine or phenylalanine at position 45. Exon 2 encodes either valine or phenylalanine at position 352 and either serine or cysteine at position 370. Either serine or proline, encoded by nucleotide changes within exon 3 may occupy
20 amino acid position 514.

The distribution of non-synonymous nucleotide changes within different *Klotho* exons shown in Table 3 indicates that they may encode at least 2 wild-type proteins and a
25 minimum of 6 hybrid proteins according to the new biochemical pathway described herein.

TABLE 3EXON LOCATION OF NUCLEOTIDE CHANGES WHICH ENCODE AMINO
ACID DIFFERENCES IN ALTERNATIVE KLOTHO ALLELES

5

	Amino acid position	Exon	Amino acid alternative
	15	1	(Q) Gln
10	15	1	(P) Pro
	45	1	(V) Val
	45	1	(F) Phe
	352	2	(V) Val
	352	2	(F) Phe
15	370	2	(C) Cys
	370	2	(S) Ser
	514	3	(S) Ser
	514	3	(P) Pro

EXAMPLE 6 CYSTIC FIBROSIS AS A MODEL FOR HV IN
COMPOUND CFTR MUTANT HETEROZYGOTES

5 Cystic fibrosis is one of the world's most common genetic disorders. It is autosomal recessive in nature and caused by inheritance of two of a large number of mutated forms of the CFTR gene. Disease manifestations reflect a form of HV as illustrated below, are highly variable and are
10 difficult to predict from the mutant haplotypes inherited by any particular individual.

The disease affects multiple organs including the lungs and pancreas and may cause severe intestinal blockage at
15 birth. In 1992, and in keeping with our technology, Hamosh and colleagues (Hamosh et al., (1992) Am. J. Hum. Genet., 51, p 245) found that patients that were homozygous for two different CFTR mutations, delta F508 and G551D, had more severe pancreatic involvement and
20 intestinal dysfunction compared to patients that had inherited the same two mutant alleles in heterozygous form. It follows from our technology that disease attenuation is brought about by synthesis of perfectly normal CFTR molecules in heterozygous, rather than
25 homozygous patients because the nucleotide changes which encode the delta F508 and G551D disease causing mutations are located within exons 10 and 11, respectively.

EXAMPLE 7 DIABETES AS A MAMMALIAN HD[®] MODEL FOR NEW
30 BIOCHEMICAL PATHWAY

Diabetes is a common serious disease in which blood glucose levels are unable to be controlled properly because of impaired insulin secretion or resistance to its
35 action. There are many different mechanistic forms of diabetes. In type 1 diabetes (diabetes of the young) insulin release is impaired because of immune attack on

- 70 -

the islet cells, the cells within the pancreas that secrete insulin. Glutamic acid decarboxylase (GAD 65) encodes a major islet cell auto-antigen targeted by the immune system in type 1 diabetes.

5

Table 4 details the exonic location of nucleotide changes that encode different amino acids in alternative allelic forms of the enzyme glutamic acid decarboxylase. Coding region sequence variations were retrieved from NCBI
10 databases. As shown in Table 4, exon 1 includes nucleotide differences that encode arginine or glycine at amino acid position 12. Exon 4, on the other hand, includes nucleotide changes that encode either asparagine or lysine at amino acid position 124 as well as glutamine or proline
15 at position 153. Table 3 also shows that the alternative amino acids glutamic acid or glycine at position 232 are encoded by nucleotide differences within exon 6, arginine or lysine at position 286 by nucleotide changes within exon 8, and either alanine or glycine at position 326 by
20 nucleotide changes within exon 10.

The distribution of nucleotide sequence differences that encode alternative amino acids and that are included in exons 1, 4, 6, 8 or 10 satisfies the structural criteria
25 that need to be fulfilled to generate hybrid forms of glutamic acid decarboxylase in subjects who are heterozygous for any two of the different allelic forms of the enzyme referred to in Table 4. For example, by reference to the alternative amino acids which can be
30 encoded by nucleotide differences located in exons 6 and 8 only, the combinations of (a) glutamic acid/arginine (b) glutamic acid/lysine (c) glycine/arginine and (d) glycine/lysine at amino acid positions 232 and 286 are formed in accordance with the new biochemical pathway. Two
35 of these combinations comprise wild-type enzymes whereas the other two comprise hybrid forms.

- 71 -

TABLE 4EXON LOCATION OF NUCLEOTIDE CHANGES WHICH ENCODE AMINO
ACID DIFFERENCES IN ALTERNATIVE GLUTAMIC ACID

5 DECARBOXYLASE (GAD65) ALLELES

	Amino acid position	Exon	Amino acid alternative
	12	1	(R) Arginine
10	12	1	(G) Glycine
	124	4	(N) Asparagine
	124	4	(K) Lysine
	153	4	(Q) Glutamine
	153	4	(P) Proline
15	232	6	(E) Glutamic acid
	232	6	(G) Glycine
	286	8	(R) Arginine
	286	8	(K) Lysine
	326	10	(A) Alanine
20	326	10	(G) Glycine

EXAMPLE 8 THE ROLE OF GAD65 HETEROZYGOSITY IN
AUTOANTIBODY INDUCTION

GAD65 auto-antibodies may be detected in the serum of
5 patients suffering Type I diabetes prior to disease onset
as well as in the serum of their asymptomatic sibs, albeit
at lower levels.

In keeping with inventors' findings and hypothesis that
10 heterozygosity for GAD65 alleles which fulfil the
structural criteria allows generation of hybrid forms of
GAD65 that enhance the immune response against GAD65,
auto-antibody levels should vary according to GAD65
genotype even in non-type I diabetic subjects. Results of
15 a recent comprehensive study by Boutin et al, (2003), *PLoS*
Biol. 1, p68 confirm that GAD65 auto-antibody levels are
significantly higher in subjects who are heterozygous for
GAD65 alleles compared to the same groups of subjects who
are homozygous for the same GAD65 alleles. These findings
20 strongly support inventors claim that novel polypeptides
or proteins, formed by the novel biochemical pathway in
subjects who are heterozygous for different forms of
alleles, which fulfil inventors structural criteria,
synthesise auto-antibodies more readily than subjects who
25 are homozygous for the same GAD65 alleles.

On the other hand, types of diabetes which occur later in
life, some of which are associated with obesity, are not
caused by an auto-immune process. These forms of diabetes
30 are referred to as type 2 diabetes. The most
consistently recognised type 2 diabetes candidate gene
located on chromosome 2 is calpain-10 (CALP-10). No mutant
forms of CALP-10 have been found to explain the
relationship between this gene and development of type 2
35 diabetes even though it is associated with the highest
risk for development of type 2 diabetes. The HD model for
the association of CALP-10 with susceptibility to

development of type 2 diabetes is strongly supported by findings that many different allelic forms of CALP-10 have been identified, such as L34V, T504A, R555C, and V666I (Evans et al., *Am. J. Genet.* 69,544 (2001)) that satisfy
5 the structural criteria that are required to form hybrid enzymes in heterozygous offspring via the novel biochemical pathway. In keeping with the model, increased susceptibility to development of type 2 diabetes has been shown to be associated with heterozygosity rather than
10 homozygosity for different allelic forms of CALP-10 (see Cox, (2001), *Hum. Mol. Genet.* 10, p2301; Cox et al., (2004), *Diabetes*, 53, p19.

Insulin-degradation enzyme (IDE) is another strong
15 candidate type 2 diabetes susceptibility gene found to be located on chromosome 10 by genomic scanning. IDE is involved in the proteolytic degradation of insulin, most likely as part of termination of the insulin response. As with CALP-10, no disease causing mutational forms of
20 IDE have been found.

The exonic location of nucleotide changes which encode different amino acids within IDE is shown in Table 5. The coding sequence variations were retrieved from NCBI
25 databases. As shown in the Table, exon 3 contains nucleotide sequence differences which encode the alternative amino acids phenylalanine or leucine at position 298. Moreover, amino acids leucine or phenylalanine may be encoded at amino acid position 582 by
30 nucleotide changes located within exon 5 and serine or glycine at amino acid position 854 may be encoded by nucleotide differences within exon 11. Asparagine or aspartic acid may be encoded at amino acid position 947 by variation in sequence included in exon 20.

35

The distribution of nucleotide sequence differences which encode alternative amino acids at positions 298, 582, 845,

- 74 -

and 947 and which are located in exons 3, 5, 11 and 20 respectively satisfy the structural criteria required to synthesise hybrid forms of IDE in subjects who are heterozygous for any two of the alternative alleles shown in Table 4. For example, with reference to alleles encoded by exons 11 and 20 only, amino acid combinations at positions 845 and 947 include (a) serine/asparagine (b) serine/aspartic acid (c) glycine/asparagine and (d) glycine/aspartic acid. Two of these combinations reflect wild-type enzymes whereas the other two comprise hybrid forms of the enzyme.

- 75 -

TABLE 5

5 EXON LOCATION OF NUCLEOTIDE CHANGES THAT ENCODE AMINO ACID
DIFFERENCES IN ALTERNATIVE IDE ALLELES.

	Amino acid position	Exon	Amino acid alternative
	298	3	(F) Phenylalanine
10	298	3	(L) Leucine
	582	5	(L) Leucine
	582	5	(F) Phenylalanine
	845	11	(S) Serine
	845	11	(G) Glycine
15	947	20	(N) Asparagine
	947	20	(D) Aspartic

- 76 -

EXAMPLE 9 THROMBOEMBOLISM AS A MAMMALIAN HD MODEL FOR
NEW BIOCHEMICAL PATHWAY

Patients suffering from systemic lupus erythematosus (SLE)
5 that develop lupus anticoagulant are susceptible to
thromboembolic disease. It is thought that development of
thromboembolic disease is due to inappropriate activation
of platelets, an integral part of the blood clotting
system. In SLE patients, platelets may be activated by
10 circulating immune complexes which bind to Fc gammaIIa
receptors on their surface or by autoantibodies directed
against them.

Results of a recent study (Schallmoser et al., (2005),
15 *Thrombosis Haemostasis* 93, p544) have shown that patients
with lupus anticoagulant are more susceptible to
development of thromboembolic disease if they are
heterozygous for alternative allelic forms of Fc gamma
IIa.

20 Table 6 shows the exon location of nucleotide changes that
encode different amino acids in alternative allelic forms
of Fc gamma IIa.

25 The coding sequence variations were retrieved from NCBI
databases. As shown in Table 6, exon 1 may encode either
arginine or glutamine at amino acid position 61 of Fc
gammaIIa, whereas exon 2 may encode valine or methionine
at amino acid position 138 and either arginine or
30 histidine at amino position 165. Exon 3 may encode proline
or leucine at amino acid position 272.

According to the invention described herein, amino acid
combinations at positions 61, 138, 165 and 272 permit the
35 formation of a minimum of 2 wild-type proteins and a
minimum of at least 6 hybrid proteins.

- 77 -

TABLE 6EXON LOCATION OF NUCLEOTIDE CHANGES WHICH ENCODE AMINO
ACID DIFFERENCES IN ALTERNATIVE FC GAMMA IIA ALLELES.

	Amino acid position	Exon	Amino acid alternative
5	61	1	(R) Arg
	61	1	(Q) Gln
10	138	2	(V) Val
	138	2	(M) Met
	165	2	(R) Arg
	165	2	(H) His
	272	3	(P) Pro
15	272	3	(L) Leu

20

EXAMPLE 10 PLANT MODEL WHICH SUPPORTS THE ROLE OF NEW
BIOCHEMICAL PATHWAY IN HV

Catalase 1 (Cat-1) is an oxidoreductase type of enzyme that plays an important role in the breakdown of hydrogen peroxide in plants. In maize, at least 6 different allelic forms of Cat-1 have been identified, most of which differ in amino acid composition.

In 1972 a hybrid form of Cat-1 (Scandalios et al., (1972), *Arch. Biochem. Biophys.* 153, p695) was identified in plants that were heterozygous for two different allelic forms of Cat-1. The hybrid Cat-1 enzyme was shown to possess a range of enhanced biochemical properties compared to either of the homozygous parental forms.

The new biochemical pathway provides a plausible explanation for the formation of hybrid Cat-1 molecules with enhanced biochemical properties compared to wild-types that does not rely on the formation of polymeric forms of the enzyme.

EXAMPLE 11 INSECT MODEL WHICH SUPPORTS THE ROLE OF NEW
BIOCHEMICAL PATHWAY IN HV

Octanol dehydrogenase (*odh*) encodes an enzyme found in *Drosophila pseudoobscura* and other flies. It is involved in the metabolism of long chained alcohols.

Two different structural forms of the enzyme *odh* have been identified, F and S based on differences in their electrophoretic mobility. In 1972, Wills and Nichols (Proc. Natl. Acad. Sci. USA 69, 323 (1972)) demonstrated that heterozygosity for each of the two different structural forms of *odh* plays a heterotic role in the survival of flies that develop on a medium impregnated with octanol. Heterotic heterozygous *odh* flies have a novel structural form of the enzyme not found in either of their parents that are homozygous for each alternative form of *odh* respectively. The new biochemical pathway provides a

plausible explanation for the formation of novel structural forms of odh in heterozygous flies that does not rely on multimerisation of the enzyme (see Singh et al., Genetics 80,637 (1975)).

5

EXAMPLE 12IDENTIFICATION OF HYBRID ASL MOLECULES

As outlined below, it is possible to prove that active argininosuccinate lyase (ASL) can be generated in offspring of affected parents by inclusion of wild-type encoding exons from each of the different mutant alleles into the same mRNA molecule by way of the newly identified biochemical pathway.

Previous studies have shown that when combinations of inactive ASL mutants such as ASL(D87G) and ASL(Q286R) are inherited in heterozygous form, activity is partially restored. Therefore, mRNA can be isolated from fibroblasts or liver of a subject who is proven to have inherited each of the two inactive allelic mutant forms of ASL. Total mRNA can then be subjected to RT-PCR using oligonucleotide primers that span individual exons. The RT-PCR products containing these regions are then cloned and sequenced.

Approximately 85% of clones generated from the RT-PCR products from the subject genotyped as ASL(D87G)/(Q286R) would confirm firstly, bi-allelic expression of ASL and cis-assembly of exons. The sequence of inserts from approximately 15% of clones however would include sequences from each of the two parental alleles in the same clone and thus generate approximately 15% of wild-type enzyme accounting for restoration of enzyme activity.

EXAMPLE 13ASSOCIATION OF HYBRID GAD65 MOLECULES WITH GAD65 AUTO-ANTIBODY PRODUCTION

Total mRNA can be extracted from islet cells of pancreatic tissue obtained from a patient suffering type 1 diabetes. If the patient is heterozygous for GAD65 alleles, which

- 80 -

have nucleotide changes in different exons which encode non-synonymous amino acids (see Table 3), the patient would have high titre GAD65 auto-antibody in his/her blood.

5

Total pancreatic mRNA can then be subjected to RT-PCR using oligonucleotide primers which span exons 1, 4, 6, 8 or 10, according to the patient's GAD65 genotype.

10 It would be expected that the sequence of inserts of approximately 85% of clones would confirm bi-allelic expression and cis-assembly of exons from each of the two alleles. The sequence of a further 15% of clones would be expected to contain inserts that confirm that a hybrid
15 form of GAD65 is synthesised in islet cells from a patient suffering type 1 diabetes who is heterozygous for different allelic forms of GAD65 as defined supra and has circulating GAD65 auto-antibodies in their blood.

20 The same experimental rationale is applicable to all species when it becomes known that the offspring under investigation has inherited genes that have alleles as defined supra and the tissues or cells in which the gene is expressed is identified.

25

The methodologies included above are meant to be examples only and do not exclude the use of any other technologies or experimental protocols familiar to anyone skilled in the art.

30

CLAIMS

1. A method for identifying candidate genes capable of producing hybrid vigour or hybrid debility in an animal or plant, comprising the steps of:
- 5 (i) comparing the mRNA sequence of alleles of candidate genes isolated from an animal or plant which exhibits hybrid vigour or hybrid debility with the nucleotide sequences from the corresponding alleles isolated from the parents of said animal or plant;
- 10 (ii) identifying mRNA sequence differences in the alleles from said animal or plant which exhibits hybrid vigour or hybrid debility which codes for amino acid sequence variation; and
- 15 (iii) identifying that the amino acid sequence variation between alleles of the candidate gene in said animal or plant is encoded by mRNA sequences which are located within two or more different exons within the candidate gene.
- 20
2. A method according to claim 1, wherein the amino acid sequence variation is a conservative modified variation.
- 25 3. A method according to claim 1, wherein the amino acid sequence variation is a non-conservative modified variation.
4. A method according to claim 1, wherein the step of identifying the mRNA sequence difference comprises the step of sequencing the mRNA isolated from said plant or animal.
- 30
5. A method according to claim 1, wherein the plant is selected from the group consisting of barley, rye, sorghum, maize, soybean, wheat, corn, potato, cotton, rice, oilseed rape (including canola), sunflower, alfalfa,
- 35

sugarcane, banana, blackberry, blueberry, strawberry, and raspberry, cantaloupe, carrot, cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce, mango, melon, onion, papaya, peas, peppers, pineapple, spinach, squash, sweet corn, tobacco, tomato, watermelon, rosaceous 5 fruits (such as apple, peach, pear, cherry and plum) and vegetable brassicas (such as broccoli, cabbage, cauliflower, brussel sprouts and kohlrabi). Other crops, fruits and vegetables whose phenotype may be changed 10 include barley, currant, avocado, citrus fruits such as oranges, lemons, grapefruit and tangerines, artichoke, cherries, nuts such as the walnut and peanut, endive, leek, roots, such as arrowroot, beet, cassava, turnip, radish, yam, sweet potato and beans.

15

6. A method according to claim 1, wherein the animal is a mammal or fish.

7. A method according to claim 6, wherein the mammal 20 is selected the mammalian Orders Primates, Rodentia, Lagomorpha, Cetacea, Carnivora, Perissodactyla and Artiodactyla.

8. A method according to claim 7, wherein the 25 Artiodactyla is selected from one of the nine families, Suidae, Tayassuidae, Hippopotamidae, Camelidae, Tragulidae, Giraffidae, Cervidae, Antilocapridae and Bovidae.

30 9. A method according to claim 8, wherein the animal selected from Bovidae is an ungulate.

10. A method according to claim 9, wherein the 35 ungulate is selected from the group consisting of cows or bulls, bison, buffalo, sheep, big-horn sheep, horses, ponies, donkeys, mule, deer, elk, caribou, goat, water buffalo, camels, llama, alpaca, and pigs.

11. A method according to claim 6, wherein the animal is a fish.

5 12. A method according to claim 11, wherein the fish is selected from the group consisting of zebrafish, European carp, salmon, mosquito fish, tench, lampreys, round gobies, tilapia and trout.

10 13. A method according to claim 8, wherein the animal is a human.

14. A method of identifying factors leading to hybrid vigour or hybrid debility comprising the steps of:

15 (i) identifying the presence or absence of multiple species of mRNA or protein encoded by alleles of a candidate gene; and

(ii) if multiple species of mRNA or protein are present then analysing said species of mRNA or protein to
20 determine if said species have nucleotide or amino acid sequence variations, respectively corresponding to variations in two or more exons;

wherein the presence of multiple species of mRNA or protein at step (ii) is indicative of hybrid vigour or
25 hybrid debility.

15. A method for producing hybrid vigour or hybrid debility in an animal or plant, comprising the steps of:

(i) identifying the presence or absence of
30 multiple species of mRNA or protein encoded by alleles of a candidate gene; and

(ii) if multiple species of mRNA or protein are present then analysing said species of mRNA or protein to
35 determine if said species have nucleotide or amino acid sequence variations, respectively corresponding to variations in two or more exons; wherein the presence of multiple species of mRNA or protein at step (ii) is

indicative of hybrid vigour or hybrid debility;

(iii) determining the function of the multiple species of proteins compared to the function of a wild-type protein control to determine which species promotes

5 HV or HD in said plant or animal;

(iv) preparing a construct comprising nucleotide sequence encoding said protein species in step (iii);

(v) transforming said construct into a recipient plant or animal cell; and

10 (vi) regenerating a plant or animal, which expresses said construct, from said cell.

16. A method of detecting the presence or absence of hybrid mRNA in a plant or animal comprising the step of
15 isolating mRNA from a plant or animal and comparing the nucleotide sequence of said mRNA to the corresponding coding sequence of the plant or animal's alleles.

17. A construct comprising a synthetic gene
20 comprising exons from different alleles of a gene, wherein said alleles code for amino acid sequence variation wherein the variation occurs between different alleles.

18. Use of hybrid mRNA molecules produced in vitro or
25 in vivo to overcome hybrid debility in a plant or animal and/or induce hybrid vigour in a plant or animal comprising the step of introducing said hybrid mRNA into said animal or plant.

30 19. Use according to claim 18, wherein the step of introducing said hybrid mRNA into said animal or plant is by transformation or homologous recombination.

20. Use according to claim 19, wherein the step of
35 transformation into a plant is selected from the group consisting of homologous recombination, microprojectile bombardment, PEG mediated transformation, electroporation,

silicon carbide fibre mediated transformation, or Agrobacterium-mediated transformation.

21. Use of hybrid protein molecules produced in vitro or in vivo to overcome hybrid debility in a plant or animal and/or induce hybrid vigour in a plant or animal comprising the step of introducing said hybrid protein into said animal or plant.
22. Use according to claim 21 wherein the step of introducing said hybrid protein into said animal, human or plant is by administering the hybrid protein orally, topically or parenterally.
23. A method of treating or preventing a disease, comprising the step of administering to an animal or plant a candidate gene identified by a method according to any one of claim 1 to 13.
24. A method of treating or preventing a disease, comprising the step of administering to an animal or plant a factor identified by a method according to claim 14.
25. A method of treating or preventing a disease, comprising the step of administering to an animal or plant a construct according to claim 17.
26. Use of a candidate gene identified by a method according to any one of claims 1 to 13 for the preparation of a medicament for the treatment or prevention of a disease.
27. Use of a factor identified by a method according to claim 14 for the preparation of a medicament for the treatment or prevention of a disease.

28. Use of a construct according to claim 17 for the preparation of a medicament for the treatment or prevention of a disease.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2006/001065

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl.		
C12Q 1/68 (2006.01)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) AGRICOLA, WPIDS, MEDLINE, CAPLUS, BIOSIS, BIOTECHABS, USPATFULL, EPFULL: hybrid vigour, hybrid debility, allele, polymorphism, polymorphism, variant, mutation, snp, microsatellite, exons		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 2005/075668 A1 (RED RABBIT PTY LTD) 18 August 2005 Whole document (note claims 1-13, 22-26 are identical to current claims 1-13, 17-20; see also page 51; line 19 to page 54, line 19)	1-15, 23-24, 26-27
A	WO 2000/042838 (PIONEER HI-BRED INTERNATIONAL, INC.) 27 July 2000 Whole document (especially pages 10, 17, 35-36 and claim 15)	
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 10 August 2006	Date of mailing of the international search report 19 SEP 2006	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer Jamie Turner Telephone No : (02) 6283 2071	

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: **16-22, 25, 28**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 16-22, 25 and 28 are not considered to be limited to the technical features of the invention. As discussed throughout the specification, the present invention hinges on the discovery that hybrid vigour and hybrid debility traits can be generated in heterozygous offspring in a biochemical pathway that incorporates exons from each of the two parental allelic transcriptional units into the same mature mRNA molecule. Because claims 16-22, 25 and 28 do not incorporate this feature, they are not considered limited to the technical features of the invention.

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU2006/001065

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member			
WO 2005075668				
WO 2000042838	AU 26213/00	CA 2358509	EP 1143787	
	HU 0200319	MX PA01007325		
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.				
END OF ANNEX				